WO2013036810A1 - Methods for tagging dna-encoded libraries - Google Patents
Methods for tagging dna-encoded libraries Download PDFInfo
- Publication number
- WO2013036810A1 WO2013036810A1 PCT/US2012/054228 US2012054228W WO2013036810A1 WO 2013036810 A1 WO2013036810 A1 WO 2013036810A1 US 2012054228 W US2012054228 W US 2012054228W WO 2013036810 A1 WO2013036810 A1 WO 2013036810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- building block
- headpiece
- tag
- nucleotides
- terminus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
- C40B50/16—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support involving encoding steps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Definitions
- this invention relates to DNA-encoded libraries of compounds and methods of using and creating such libraries.
- the invention also relates to compositions for use in such libraries.
- DNA-encoded combinatorial libraries afford many benefits for drug discovery. These libraries can provide a large number of diverse compounds that can be rapidly screened and interrogated. To further increase complexity, various steps of the discovery process can be programmed and automated. These steps include the use of multi-step, split-and-pool synthesis to add building blocks to atomic or polyatomic scaffolds and the use of enzymatic and/or chemical ligation to add DNA tags that encode both the synthetic steps and the building blocks.
- the present invention features methods of creating libraries, where the method includes one or more conditions that improve single-stranded ligation of tags, and compositions for use in creating libraries.
- Exemplary conditions include the use of one or more 2'-substituted bases within the tags, such as 2 '-0 -methyl or 2'-fluoro; the use of tags of particular length; the use of one or more enzymes;
- the invention features a method of tagging a first library including an
- oligonucleotide-encoded chemical entity including: (i) providing a headpiece having a first functional group and a second functional group, where the headpiece includes at least one 2 '-substituted nucleotide; (ii) binding the first functional group of the headpiece to a first component of the chemical entity, where the headpiece is directly connected to the first component or the headpiece is indirectly connected to the first component by a bifunctional linker (e.g., a poly ethylene glycol linker or—
- a bifunctional linker e.g., a poly ethylene glycol linker or—
- steps (ii) and (iii) can be performed in any order and where the first building block tag encodes for the binding reaction of step (ii), thereby providing a tagged library.
- the headpiece includes a 2 '-substituted nucleotide at one or more of the 5 '-terminus, the 3 '-terminus, or the internal position of the headpiece.
- the headpiece includes the 2 '-substituted nucleotide and the second functional group at the 5'-terminus or at the 3 '-terminus.
- the first building block tag includes at least one (e.g., at least two, three, four, five, or more) 2 '-substituted nucleotides.
- the first building block tag includes a 2'-substituted nucleotide at one or more of the 5'-terminus, the 3'-terminus, or the internal position of the first building block tag (e.g., a 2'-0-methyl nucleotide or a 2'-fluoro nucleotide at both of the 5'- and 3'-termini).
- the first building block tag includes a protecting group at the 3 '-terminus or at the 5 '-terminus.
- the 2'-substituted nucleotide is a 2'-0-methyl nucleotide (e.g., 2'-0-methyl guanine or 2'-0-methyl uracil) or a 2'-fluoro nucleotide (e.g., 2'-fluoro guanine, or 2'-fluoro uracil).
- a 2'-0-methyl nucleotide e.g., 2'-0-methyl guanine or 2'-0-methyl uracil
- a 2'-fluoro nucleotide e.g., 2'-fluoro guanine, or 2'-fluoro uracil
- step (ii) may include joining, binding, or operatively associating the headpiece directly to the first component (e.g., a scaffold or a first building block).
- step (ii) includes binding the headpiece indirectly to the first component (e.g., a scaffold or a first building block) via a bifunctional linker (e.g., the method includes binding the headpiece with the first functional group of the linker and binding the first component with the second functional group of the linker).
- the method may further include (iv) binding a second building block tag to the 5'-terminus or 3'-terminus of the complex; and (v) binding a second component (e.g., a first building block or a second building block) of the chemical library to the first component, where steps (iv) and (v) can be performed in any order.
- the second building block tag encodes for the binding reaction of step (v).
- step (iv) may include binding the second building block tag to the 5 '-terminus of the complex; the complex includes a phosphate group at the 5'- terminus; and the second building block tag includes a hydroxyl group at both of the 3' - and 5 '-termini.
- step (iv) may further include purifying the complex and reacting the complex with a polynucleotide kinase to form a phosphate group on the 5 '-terminus prior to binding the second building block tag.
- step (iv) may include binding the second building block tag to the 3'-terminus of the complex; the complex includes a protecting group at the 3'-terminus; and the second building block tag includes a phosphate group at the 5 '-terminus and a protecting group at the 3'- terminus.
- step (iv) may further include reacting the complex with a hydrolyzing agent to release the protecting group from the complex prior to binding the second building block tag to the complex.
- the second building block tag includes a 2' -substituted nucleotide (e.g., a 2'-0-methyl nucleotide or a 2'-fluoro nucleotide) at one or more of the 5'-terminus, the 3'-terminus, or the internal position of the second building block tag (e.g., a 2'-0-methyl nucleotide and/or a 2'-fluoro nucleotide at both of the 5'- and 3 '-termini).
- a 2' -substituted nucleotide e.g., a 2'-0-methyl nucleotide or a 2'-fluoro nucleotide
- step (iv) may include the use of an RNA ligase (e.g., T4 RNA ligase) and/or a DNA ligase (e.g., a ssDNA ligase) to bind the second building block tag to the complex (e.g., may include the use of both RNA ligase and the DNA ligase).
- an RNA ligase e.g., T4 RNA ligase
- a DNA ligase e.g., a ssDNA ligase
- step (iii) may include the use of an RNA ligase (e.g., T4 RNA ligase) and/or a DNA ligase (e.g., ssDNA ligase) to bind the headpiece to the first building block tag (e.g., may include the use of both RNA ligase and the DNA ligase).
- an RNA ligase e.g., T4 RNA ligase
- a DNA ligase e.g., ssDNA ligase
- step (iii) and/or step (iv), if present, may include the use of poly ethylene glycol and/or one or more soluble multivalent cations (e.g., magnesium chloride, manganese (II) chloride, or hexamine cobalt (III) chloride).
- the poly ethylene glycol is in an amount from about 25% (w/v) to about 35% (w/v) (e.g., from about 25% (w/v) to about 30 % (w/v), from about 30 % (w/v) to about 35% (w/v), or about 30% (w/v)).
- the poly ethylene glycol has an average molecular weight from about 3,000 to about 5,500 Daltons (e.g., about 4,600 Daltons).
- the one or more soluble multivalent cations are in an amount of from about 0.05 mM to about 10.5 mM (e.g., from 0.05 mM to 0.5 mM, from 0.05 mM to 0.75 mM, from 0.05 mM to 1.0 mM, from 0.05 mM to 1.5 mM, from 0.05 mM to 2.0 mM, from 0.05 mM to 3.0 mM, from 0.05 mM to 4.0 mM, from 0.05 mM to 5.0 mM, from 0.05 mM to 6.0 mM, from 0.05 mM to 7.0 mM, from 0.05 mM to 8.0 mM, from 0.05 mM to 9.0 mM, from 0.05 mM to 10.0 mM, from 0.1 mM to
- one or more multivalent cations are in an amount of about 1 mM (e.g., from 0.5 mM to 1.5 mM).
- the multivalent cation is in the form of hexamine cobalt (III) chloride.
- the method further includes separating the complex from any unreacted tag or unreacted headpiece before any one of binding steps (ii)-(v). In other embodiments, the method further includes purifying the complex before any one of binding steps (ii)-(v). In other embodiments, the method further includes binding one or more additional components (e.g., a scaffold or a first building block) and one or more additional building block tags, in any order and after any one of binding step (ii)- (v).
- additional components e.g., a scaffold or a first building block
- the invention also features a method of tagging a first library including an oligonucleotide- encoded chemical entity, the method including: (i) providing a headpiece having a first functional group and a second functional group, where the headpiece includes a 2 '-substituted nucleotide at the 5'- terminus, optionally one or more nucleotides at the internal position of the headpiece, and a protecting group at the 2 '-position and/or the 3 '-position at the 3 '-terminus; (ii) binding the first functional group of the headpiece to a first component of the chemical entity, where the headpiece is directly connected to the first component or the headpiece is indirectly connected to the first component by a bifunctional linker; and (iii) binding the second functional group of the headpiece to a first building block tag, where the first building block tag includes a 2 '-substituted nucleotide and a hydroxyl group at the 5'-terminus, optionally one or more nu
- the 2 '-substituted nucleotide is a 2'-0-methyl nucleotide (e.g., 2'-0- methyl guanine) or a 2'-fluoro nucleotide (e.g., 2'-fluoro guanine).
- one or more nucleotides at the internal position of the headpiece are 2'-deoxynucleotides.
- the bifunctional linker is a poly ethylene glycol linker (e.g., -(CH 2 CH 2 0) n CH 2 CH 2 -, where n is an integer from 1 to 50).
- one or more nucleotides are present at the internal position of the headpiece or the tag.
- step (iii) may include the use of one or more soluble multivalent cations (e.g., magnesium chloride, manganese (II) chloride, or hexamine cobalt (III) chloride), poly ethylene glycol (e.g., having an average molecular weight of about 4,600 Daltons), and RNA ligase (e.g., T4 RNA ligase).
- one or more soluble multivalent cations e.g., magnesium chloride, manganese (II) chloride, or hexamine cobalt (III) chloride
- poly ethylene glycol e.g., having an average molecular weight of about 4,600 Daltons
- RNA ligase e.g., T4 RNA ligase
- the invention features methods to identify and/or discover a chemical entity, the method including tagging a first library including an oligonucleotide-encoded chemical entity (e.g., including steps (i) to (iii) and optionally including steps (iv) to (v)) and selecting for a particular characteristic or function (e.g., selecting for binding to a protein target including exposing the oligonucleotide-encoded chemical entity or chemical entity to the protein target and selecting the one or more oligonucleotide-encoded chemical entities or chemical entities that bind to the protein target (e.g., by using size exclusion chromatography)).
- a particular characteristic or function e.g., selecting for binding to a protein target including exposing the oligonucleotide-encoded chemical entity or chemical entity to the protein target and selecting the one or more oligonucleotide-encoded chemical entities or chemical entities that bind to the protein target (e.g., by using size exclusion
- the invention also features a complex including a headpiece and a building block tag, where the tag includes from 5 to 20 nucleotides, a 2 '-substituted nucleotide at the 5'-terminus, and a 2'-substituted nucleotide at the 3'-terminus.
- the 2'- substituted nucleotide at the 5 '-terminus and/or 3'-terminus is a 2'-0-methyl nucleotide (e.g., 2'-0- methyl guanine or 2'-0-mefhyl uracil) or a 2'-fluoro nucleotide (e.g., 2'-fluoro guanine or 2'-fluoro uracil).
- the headpiece includes a hairpin structure.
- the headpiece includes a 2 '-substituted nucleotide at one or more of the 5'-terminus, the 3'-terminus, or the internal position of the headpiece.
- the headpiece further includes a preadenylated 5 '-terminus.
- the headpiece includes from 5 to 20 nucleotides.
- the headpiece, the first building block tag, the second building block tag, or the one or more additional building block tags, if present, includes a preadenylated 5'- terminus.
- the method further includes binding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) additional building block tags to the complex and binding one or more (e.g., one, two, three, four, five, six, seven, eight, nine, or ten) additional components (e.g., scaffolds or building blocks) to the complex, where the one or more additional building block tag encodes for the one or more additional components or encodes for the binding reaction of one or more additional components, thereby providing a tagged library.
- one or more e.g., one, two, three, four, five, six, seven, eight, nine, or ten
- additional components e.g., scaffolds or building blocks
- the 2 '-substituted nucleotide is a 2'-0-methyl nucleotide, such as 2'-0-methyl guanine, 2'-0-methyl uracil, 2'-0-methyl adenosine, 2'-0-methyl thymidine, 2'-0- methyl inosine, 2'-0-methyl cytidine, or 2'-0-methyl diamino purine.
- a 2'-0-methyl nucleotide such as 2'-0-methyl guanine, 2'-0-methyl uracil, 2'-0-methyl adenosine, 2'-0-methyl thymidine, 2'-0- methyl inosine, 2'-0-methyl cytidine, or 2'-0-methyl diamino purine.
- the 2'-substituted nucleotide is a 2'-fluoro nucleotide, such as 2'-fluoro guanine, 2'-fluoro uracil, 2'-fluoro adenosine, 2'-fluoro thymidine, 2'-fluoro inosine, 2'-fluoro cytidine, or 2'-fluoro diamino purine.
- 2'-fluoro nucleotide such as 2'-fluoro guanine, 2'-fluoro uracil, 2'-fluoro adenosine, 2'-fluoro thymidine, 2'-fluoro inosine, 2'-fluoro cytidine, or 2'-fluoro diamino purine.
- the RNA ligase is T4 RNA ligase and/or the DNA ligase is a ssDNA ligase.
- the method includes a plurality of headpieces.
- each headpiece of the plurality of headpieces includes an identical sequence region and a different encoding region.
- the identical sequence region is a primer binding region.
- the different encoding region is an initial building block tag that encodes for the headpiece or for an addition of an initial component.
- binding in at least one of steps (ii)-(iv), if present, includes enzyme ligation and/or chemical ligation.
- enzymatic ligation includes use of an RNA ligase (e.g., T4 RNA ligase) or a DNA ligase (e.g., ssDNA ligase).
- enzymatic ligation includes use of an RNA ligase (e.g., T4 RNA ligase) and a DNA ligase (e.g., ssDNA ligase).
- chemical ligation includes use of one or more chemically co-reactive pairs (e.g., a pair including an optionally substituted alkynyl group with an optionally substituted azido group; a pair including an optionally substituted diene having a 4 ⁇ electron system (e.g., an optionally substituted 1,3 -unsaturated compound, such as optionally substituted 1,3 -butadiene, l-methoxy-3- trimethylsilyloxy-l,3-butadiene, cyclopentadiene, cyclohexadiene, or furan) with an optionally substituted dienophile or an optionally substituted heterodienophile having a 2 ⁇ electron system (e.g., an optionally substituted alkenyl group or an optionally substituted alkynyl group); a pair including a nucleophile (e.g., an optionally substituted amine or an optionally substituted thiol) with a strained heterocyclyl electro
- the chemically co-reactive pair produces a resultant spacer having a length from about 4 to about 24 atoms (e.g., from about 4 to about 10 atoms).
- chemical ligation includes use of a phosphorothioate group (e.g., at the 3'-terminus) and an iodo group (e.g., at the 5'-terminus).
- chemical ligation includes a splint oligonucleotide in the binding reaction.
- the chemical ligation includes use of a phosphorothioate group (e.g., at the 3 '-terminus of the headpiece, the first building block tag, the second building block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin tag, if present), an iodo group (e.g., at the 5 '-terminus of the headpiece, the first building block tag, the second building block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin tag, if present), and a splint oligonucleotide in the binding reaction, where the use avoids use of one or more protecting groups.
- chemical ligation of multiple tags comprises alternating use of orthogonal chemically co-reactive pairs (e.g., any two or more chemically co-reactive pairs described herein) for ligating successive tags.
- the headpiece may include a single-stranded (e.g., hairpin) structure.
- the headpiece, the first building block tag, the second building block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin tag includes a sequence that is substantially identical (e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to any sequence described herein (e.g., the sequence in any one of SEQ ID NOs: 6-21 , 26, 27, or 29-3 1 ), or a sequence that is
- sequences that are substantially identical e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical
- sequence described herein e.g., the sequence in any one of SEQ ID NOs: 6-21, 26, 27, or 29-31).
- the first building block tag, the second building block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin tag, if present further includes a sequence that is substantially identical (e.g., at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
- the methods or complexes include only single-stranded molecules, where the headpiece, the first building block tag, the second building block tag, and/or the one or more additional building block tags are single-stranded.
- one or more of the single-stranded molecules have a hairpin structure.
- the headpiece includes a hairpin structure and the one or more building block tags do not include a hairpin structure.
- the method further comprises one or more optional steps to diversify the library or to interrogate the members of the library, as described herein.
- the method further comprises identifying a small drug-like library member that binds or inactivates a protein of therapeutic interest.
- the method further comprises contacting a member of the library with a biological target under conditions suitable for at least one member of the library to bind to the target, removing one or more library members that do not bind to the target, and analyzing the one or more oligonucleotide tags associated with them.
- the methods and complexes include a headpiece, one or more building block tags, a complex, a chemical entity, a molecule, or any member of a tagged library having decreased mass, increased solubility (e.g., in an organic solvent), decreased cost, increased reactivity, increased target accessibility, decreased hydrodynamic radius, and/or increased accuracy of analytical assessments, as compared to a method including one or more double-stranded molecules (e.g., a double-stranded headpiece or a double-stranded building block tag).
- a method including one or more double-stranded molecules e.g., a double-stranded headpiece or a double-stranded building block tag.
- each of the building block tags (e.g., the first building block tag, the second building block tag, and/or one or more additional building block tags, if present) has about the same mass (e.g., each building block tag has a mass that is about +/- 10% from the average mass between two or more building block tags).
- the building block tag has a decreased mass (e.g., less than about 15,000 Daltons, about 14,000 Daltons, about 13,000 Daltons, about 12,000 Daltons, about 1 1 ,000 Daltons, about 10,000 Daltons, about 9,000 Daltons, about 8,000 Daltons, about 7,500 Daltons, about 7,000 Daltons, about 6,000 Daltons, about 6,500 Daltons, about 5,000 Daltons, about 5,500 Daltons, about 4,000 Daltons, about 4,500 Daltons, or about 3,000 Daltons) compared to a double-stranded tag (e.g., a double-stranded tag having a mass of about 15,000 Daltons, about 14,000 Daltons, about 13,000 Daltons, or about 12,000 Daltons).
- a double-stranded tag e.g., a double-stranded tag having a mass of about 15,000 Daltons, about 14,000 Daltons, about 13,000 Daltons, or about 12,000 Daltons.
- the building block tag has a reduced length compared to a double-stranded tag (e.g., a double-stranded tag having a length of less than about 20 nucleotides, less than about 19 nucleotides, less than about 18 nucleotides, less than about 17 nucleotides, less than about 16 nucleotides, less than about 15 nucleotides, less than about 14 nucleotides, less than about 13 nucleotides, less than about 12 nucleotides, less than about 11 nucleotides, less than about 10 nucleotides, less than about 9 nucleotides, less than about 8 nucleotides, or less than about 7 nucleotides).
- a double-stranded tag having a length of less than about 20 nucleotides, less than about 19 nucleotides, less than about 18 nucleotides, less than about 17 nucleotides, less than about 16 nucleotides, less than about 15 nucleotides
- one or more building block tags or members of the library lack a primer binding region and/or a constant region (e.g., during a selection step, such as selection using size exclusion chromatography).
- one or more building block tags or members of the library have a reduced constant region (e.g., a length less than about 30 nucleotides, less than about 25 nucleotides, less than about 20 nucleotides, less than about 19 nucleotides, less than about 18 nucleotides, less than about 17 nucleotides, less than about 16 nucleotides, less than about 15 nucleotides, less than about 14 nucleotides, less than about 13 nucleotides, less than about 12 nucleotides, less than about 1 1 nucleotides, less than about 10 nucleotides, less than about 9 nucleotides, less than about 8 nucleotides, or less than about 7 nucleotides).
- the methods include a headpiece that encodes for a molecule, a portion of a chemical entity, a binding reaction (e.g., chemical or enzymatic ligation) of a step, or the identity of a library, where the encoding headpiece eliminates the need of an additional building block tag to encode such information.
- a binding reaction e.g., chemical or enzymatic ligation
- an oligonucleotide encodes for the identity of the library.
- the oligonucleotide e.g., the headpiece, the first building block tag, the second building block tag, and/or one or more additional building block tags, if present
- the oligonucleotide includes a first library-identifying sequence, where the sequence encodes for the identity of the first library.
- the oligonucleotide is a first library-identifying tag.
- the method includes providing a first library-identifying tag, where the tag includes a sequence that encodes for a first library, and/or binding the first library-identifying tag to the complex. In some embodiments, the method includes providing a second library and combining the first library with a second library. In further embodiments, the method includes providing a second library-identifying tag, where the tag includes a sequence that encodes for a second library.
- an oligonucleotide encodes for the use of the member of the library (e.g., use in a selection step or a binding step, as described herein).
- the oligonucleotide e.g., the headpiece, the first building block tag, the second building block tag, and/or one or more additional building block tags, if present
- the oligonucleotide includes a use sequence, where the sequence encodes for use of a subset of members in the library in one or more steps (e.g., a selection step and/or a binding step).
- the oligonucleotide is a use tag including a use sequence.
- an oligonucleotide encodes for the origin of the member of the library (e.g., in a particular part of the library).
- the oligonucleotide e.g., the headpiece, the first building block tag, the second building block tag, and/or one or more additional building block tags, if present
- includes an origin sequence e.g., a random degenerate sequence having a length of about 10, 9, 8, 7, or 6 nucleotides
- the oligonucleotide is an origin tag including an origin sequence.
- the method further includes joining, binding, or operatively associating a use tag and/or an origin tag to the complex.
- the methods, compositions, and complexes optionally include a tailpiece, where the tailpiece includes one or more of a library-identifying sequence, a use sequence, or an origin sequence, as described herein.
- the methods further include joining, binding, or operatively associating the tailpiece (e.g., including one or more of a library-identifying sequence, a use sequence, or an origin sequence) to the complex.
- a modified phosphate group e.g., a phosphorothioate or a 5'-N-phosphoramidite linkage
- a modified phosphate group e.g., a phosphorothioate or a 5'-N-phosphoramidite linkage
- the modified phosphate group minimizes shuffling during enzymatic ligation between two oligonucleotides (e.g., minimizes inclusion of an additional nucleotide or excision of a nucleotide in the final product or complex, as compared to the sequences of two oligonucleotides to be ligated, such as between a headpiece to a building block tag or between a first building block tag and a second building block tag), as compared to ligation between two oligonucleotides (e.g., a headpiece and a building block tag or a first building block tag and a second building block tag) lacking the modified phosphate group.
- the complex may include a phosphorothioate or a triazole group.
- the methods, compositions, and complexes, or portions thereof includes a modification that supports solubility in semi-, reduced-, or non-aqueous (e.g., organic) conditions.
- the bifunctional linker, headpiece, or one or more building block tags is modified to increase solubility of a member of said DNA-encoded chemical library in organic conditions
- the modification is one or more of an alkyl chain, a polyethylene glycol unit, a branched species with positive charges, or a hydrophobic ring structure.
- the modification includes one or more modified nucleotides having a hydrophobic moiety (e.g., modified at the C5 positions of T or C bases with aliphatic chains, such as in 5'-dimethoxytrityl-N4-diisobutylaminomethylidene-5-(l-propynyl)-2'- deoxycytidine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5'-dimethoxytrityl-5-(l- propynyl)-2'-deoxyuridine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5'-dimethoxytrityl-5- fluoro-2'-deoxyuridine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphorami
- the member of the library has an octanokwater coefficient from about 1.0 to about 2.5 (e.g., about 1.0 to about 1.5, about 1.0 to about 2.0, about 1.3 to about 1.5, about 1.3 to about 2.0, about 1.3 to about 2.5, about 1.5 to about 2.0, about 1.5 to about 2.5, or about 2.0 to about 2.5).
- the headpiece, the tailpiece, the first building block tag, the second building block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin tag, if present may include from 5 to 20 nucleotides (e.g., from 5 to 7 nucleotides, from 5 to 8 nucleotides, from 5 to 9 nucleotides, from 5 to 10 nucleotides, from 5 to 1 1 nucleotides, from 5 to 12 nucleotides, from 5 to 13 nucleotides, from 5 to 14 nucleotides, from 5 to 15 nucleotides, from 5 to 16 nucleotides, from 5 to 17 nucleotides, from 5 to 18 nucleotides, from 5 to 19 nucleotides, from 6 to 7 nucleotides, from 6 to 8 nucleotides, from 6 to 9 nucleotides, from 6 to 10 nucleotides, from 6 to 11 nucleotides
- nucleotides from 12 to 19 nucleotides, from 12 to 20 nucleotides, from 13 to 14 nucleotides, from 13 to 15 nucleotides, from 13 to 16 nucleotides, from 13 to 17 nucleotides, from 13 to 18 nucleotides, from 13 to 19 nucleotides, from 13 to 20 nucleotides, from 14 to 15 nucleotides, from 14 to 16 nucleotides, from 14 to 17 nucleotides, from 14 to 18 nucleotides, from 14 to 19 nucleotides, from 14 to 20 nucleotides, from 15 to 16 nucleotides, from 15 to 17 nucleotides, from 15 to 18 nucleotides, from 15 to
- nucleotides from 15 to 20 nucleotides, from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16 to 19 nucleotides, from 16 to 20 nucleotides, from 17 to 18 nucleotides, from 17 to 19 nucleotides, from
- the headpiece, the first building block tag, the second building block tag, the one or more additional building block tags, the library-identifying tag, the use tag, and/or the origin tag, if present, have a length of less than 20 nucleotides (e.g., less than 19 nucleotides, less than
- nucleotides less than 17 nucleotides, less than 16 nucleotides, less than 15 nucleotides, less than 14 nucleotides, less than 13 nucleotides, less than 12 nucleotides, less than 11 nucleotides, less than 10 nucleotides, less than 9 nucleotides, less than 8 nucleotides, or less than 7 nucleotides).
- the first building block tag and the second building block tag include the same number of nucleotides.
- either the first building block tag or the second building block tag includes more than 8 nucleotides (e.g., more than 9 nucleotides, more than 10 nucleotides, more than 11 nucleotides, more than 12 nucleotides, more than 13 nucleotides, more than 14 nucleotides, and more than 15 nucleotides).
- the first building block tag is a donor tag (e.g., as defined herein) having from 8 to 20 nucleotides (e.g., from 8 to 9 nucleotides, from 8 to 10 nucleotides, from 8 to 11 nucleotides, from 8 to 12 nucleotides, from 8 to 13 nucleotides, from 8 to 14 nucleotides, from 8 to 15 nucleotides, from 8 to 16 nucleotides, from 8 to 17 nucleotides, from 8 to 18 nucleotides, from 8 to 19 nucleotides, from 8 to 20 nucleotides, from 9 to 10 nucleotides, from 9 to 1 1 nucleotides, from 9 to 12 nucleotides, from 9 to 13 nucleotides, from 9 to 14 nucleotides, from 9 to 15 nucleotides, from 9 to 16 nucleotides, from 9 to 17 nucleotides, from 9 to 18 nucleotides, from 9 to 20 nucle
- nucleotides from 12 to 20 nucleotides, from 13 to 14 nucleotides, from 13 to 15 nucleotides, from 13 to 16 nucleotides, from 13 to 17 nucleotides, from 13 to 18 nucleotides, from 13 to 19 nucleotides, from 13 to 20 nucleotides, from 14 to 15 nucleotides, from 14 to 16 nucleotides, from 14 to 17 nucleotides, from 14 to 18 nucleotides, from 14 to 19 nucleotides, from 14 to 20 nucleotides, from 15 to 16 nucleotides, from 15 to 17 nucleotides, from 15 to 18 nucleotides, from 15 to 19 nucleotides, from 15 to
- nucleotides from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16 to 19 nucleotides, from 16 to 20 nucleotides, from 17 to 18 nucleotides, from 17 to 19 nucleotides, from 17 to 20 nucleotides, from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16 to 19 nucleotides, from 16 to 20 nucleotides, from 17 to 18 nucleotides, from 17 to 19 nucleotides, from 17 to 20 nucleotides, from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16 to 19 nucleotides, from 16 to 20 nucleotides, from 17 to 18 nucleotides, from 17 to 18 nucleotides, from 17 to 19 nucleotides, from 17 to 20 nucleotides, from 16 to 17 nucleotides, from 16 to 18 nucleotides, from 16 to 19 nucleotides
- 2 '-substituted nucleotide is meant a nucleotide base having a substitution at the 2'-position of ribose in the base.
- bifunctional is meant having two reactive groups that allow for binding of two chemical moieties.
- a bifunctional linker is a linker, as described herein, having two reactive groups that allow for binding of a headpiece and a chemical entity
- binding is meant attaching by a covalent bond or a non-covalent bond.
- Non-covalent bonds include those formed by van der Waals forces, hydrogen bonds, ionic bonds, entrapment or physical encapsulation, absorption, adsorption, and/or other intermolecular forces. Binding can be effectuated by any useful means, such as by enzymatic binding (e.g., enzymatic ligation) or by chemical binding (e.g., chemical ligation).
- building block is meant a structural unit of a chemical entity, where the unit is directly linked to other chemical structural units or indirectly linked through the scaffold.
- the building blocks are the monomelic units of the polymer or oligomer.
- Building blocks can have one or more diversity nodes that allow for the addition of one or more other building blocks or scaffolds.
- each diversity node is a functional group capable of reacting with one or more building blocks or scaffolds to form a chemical entity.
- the building blocks have at least two diversity nodes (or reactive functional groups), but some building blocks may have one diversity node (or reactive functional group).
- the encoded chemical or binding steps may include several chemical components (e.g., multi-component condensation reactions or multi-step processes).
- Reactive groups on two different building blocks should be complementary, i.e., capable of reacting together to form a covalent or a non-covalent bond.
- building block tag is meant an oligonucleotide portion of the library that encodes the addition (e.g., by a binding reaction) of a component (i.e., a scaffold or a building block), the headpiece in the library, the identity of the library, the use of the library, and/or the origin of a library member.
- acceptor tag is meant a building block tag having a reactive entity (e.g., a hydroxyl group at the 3'- terminus in the case of enzymatic ligation).
- donor tag is meant a building block tag having an entity capable of reacting with the reactive entity on the acceptor tag (e.g., a phosphoryl group at the 5'- terminus in the case of enzymatic ligation).
- chemical entity is meant a compound comprising one or more building blocks and optionally a scaffold.
- the chemical entity can be any small molecule or peptide drug or drug candidate designed or built to have one or more desired characteristics, e.g., capacity to bind a biological target, solubility, availability of hydrogen bond donors and acceptors, rotational degrees of freedom of the bonds, positive charge, negative charge, and the like.
- the chemical entity can be reacted further as a bifunctional or trifunctional (or greater) entity.
- chemically co-reactive pair is meant a pair of reactive groups that participates in a modular reaction with high yield and a high thermodynamic gain, thus producing a spacer.
- exemplary reactions and chemically co-reactive pairs include a Huisgen 1 ,3-dipolar cycloaddition reaction with a pair of an optionally substituted alkynyl group and an optionally substituted azido group; a Diels-Alder reaction with a pair of an optionally substituted diene having a 4 ⁇ electron system and an optionally substituted dienophile or an optionally substituted heterodienophile having a 2 ⁇ electron system; a ring opening reaction with a nucleophile and a strained heterocyclyl electrophile; a splint ligation reaction with a phosphorothioate group and an iodo group; and a reductive amination reaction with an aldehyde group and an amino group, as described herein.
- complex or “ligated complex” is meant a headpiece that is operatively associated with a chemical entity and/or one or more oligonucleotide tags by a covalent bond or a non-covalent bond.
- the complex can optionally include a bifunctional linker between the chemical entity and the headpiece.
- component of a chemical entity is meant either a scaffold or a building block.
- diversity node is meant a functional group at a position in the scaffold or the building block that allows for adding another building block.
- headpiece is meant a starting oligonucleotide for library synthesis that is operatively linked to a component of a chemical entity and to a building block tag.
- a bifunctional linker connects the headpiece to the component.
- library is meant a collection of molecules or chemical entities.
- the molecules or chemical entities are bound to one or more oligonucleotides that encodes for the molecules or portions of the chemical entity.
- linker is meant a chemical connecting entity that links the headpiece to a chemical entity.
- multivalent cation is meant a cation capable of forming more than one bond with more than one ligand or anion. The multivalent cation can form either an ionic complex or a coordination complex. Exemplary multivalent cations include those from the alkali earth metals (e.g., magnesium) and transition metals (e.g., manganese (II) or cobalt (III)), and those that are optionally bound to one or more anions and/or one or more univalent or polydentate ligands, such as chloride, amine, and/or ethylenediamine.
- alkali earth metals e.g., magnesium
- transition metals e.g., manganese (II) or cobalt (III)
- univalent or polydentate ligands such as chloride, amine, and/or ethylenediamine.
- oligonucleotide is meant a polymer of nucleotides having a 5'-terminus, a 3'-terminus, and one or more nucleotides at the internal position between the 5'- and 3 '-termini.
- the oligonucleotide may include DNA, RNA, or any derivative thereof known in the art that can be synthesized and used for base- pair recognition.
- the oligonucleotide does not have to have contiguous bases but can be interspersed with linker moieties.
- the oligonucleotide polymer may include natural bases (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, deoxycytidine, inosine, or diamino purine), base analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-mefhyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-mefhylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine,
- natural bases e.g., adenosine
- modified nucleotides e.g., 2'-substituted nucleotides, such as 2'-0-methylated bases and 2'-fluoro bases
- intercalated bases modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose), and/or modified phosphate groups (e.g., phosphorothioates and 5' -N-phosphoramidite linkages).
- modified bases are described herein.
- acceptor oligonucleotide an oligonucleotide having a reactive entity (e.g., a hydroxyl group at the 3 '-terminus in the case of enzymatic ligation or an optionally substituted azido group in the case of chemical ligation).
- donor oligonucleotide an oligonucleotide having an entity capable of reacting with the reactive entity on the acceptor oligonucleotide (e.g., a phosphoryl group at the 5'- terminus in the case of enzymatic ligation or an optionally substituted alkynyl group in the case of chemical ligation).
- operatively linked or “operatively associated” is meant that two or more chemical structures are directly or indirectly linked together in such a way as to remain linked through the various manipulations they are expected to undergo.
- the chemical entity and the headpiece are operatively linked in an indirect manner (e.g., covalently via an appropriate linker).
- the linker may be a biiunctional moiety with a site of attachment for chemical entity and a site of attachment for the headpiece.
- the chemical entity and the oligonucleotide tag can be operatively linked directly or indirectly (e.g., covalently via an appropriate linker).
- protecting group is a meant a group intended to protect the 3' -terminus or 5' -terminus of an oligonucleotide against undesirable reactions during one or more binding steps of tagging a DNA- encoded library.
- Commonly used protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 4 th Edition (John Wiley & Sons, New York, 2007), which is incorporated herein by reference.
- Exemplary protecting groups include irreversible protecting groups, such as
- dideoxynucleotides and dideoxynucleosides (ddNTP or ddN), and, more preferably, reversible protecting groups for hydroxyl groups, such as ester groups (e.g., 0-(a-methoxyethyl)ester, O-isovaleryl ester, and O-levulinyl ester), trityl groups (e.g., dimethoxytrityl and monomethoxytrityl), xanthenyl groups (e.g., 9- phenylxanthen-9-yl and 9-(p-methoxyphenyl)xanthen-9-yl), acyl groups (e.g., phenoxyacetyl and acetyl), and silyl groups (e.g., t-butyldimethylsilyl).
- ester groups e.g., 0-(a-methoxyethyl)ester, O-isovaleryl este
- purifying is meant removing any unreacted product or any agent present in a reaction mixture that may reduce the activity of a chemical or biological agent to be used in a successive step. Purifying can include one or more of chromatographic separation, electrophoretic separation, and precipitation of the unreacted product or reagent to be removed.
- scaffold is meant a chemical moiety that displays one or more diversity nodes in a particular special geometry. Diversity nodes are typically attached to the scaffold during library synthesis, but in some cases one diversity node can be attached to the scaffold prior to library synthesis
- the scaffold is derivatized such that it can be orthogonally deprotected during library synthesis and subsequently reacted with different diversity nodes.
- small molecule drug or small molecule drug candidate is meant a molecule that has a molecular weight below about 1 ,000 Daltons. Small molecules may be organic or inorganic, isolated (e.g., from compound libraries or natural sources), or obtained by derivatization of known compounds.
- substantially identical is meant a polypeptide or polynucleotide sequence that has the same polypeptide or polynucleotide sequence, respectively, as a reference sequence, or has a specified percentage of amino acid residues or nucleotides, respectively, that are the same at the corresponding location within a reference sequence when the two sequences are optimally aligned.
- an amino acid sequence that is “substantially identical” to a reference sequence has at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the reference amino acid sequence.
- the length of comparison sequences will generally be at least 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous amino acids, more preferably at least 25, 50, 75, 90, 100, 150, 200, 250, 300, or 350 contiguous amino acids, and most preferably the full-length amino acid sequence.
- the length of comparison sequences will generally be at least 5 contiguous nucleotides, preferably at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides, and most preferably the full length nucleotide sequence.
- Sequence identity may be measured using sequence analysis software on the default setting (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software may match similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.
- tailpiece an oligonucleotide portion of the library that is attached to the complex after the addition of all of the building block tags and encodes for the identity of the library, the use of the library, and/or the origin of a library member.
- Figure 1 shows an exemplary method for the general synthesis of chemical libraries using single- stranded DNA tags that are joined sequentially by means of enzymatic and/or chemical ligation.
- BB refers to building block.
- Figures 2A-2B show exemplary methods for single-stranded DNA tagging of libraries using enzymatic ligation.
- Figure 2A shows an exemplary method for tagging libraries using single-stranded enzymatic ligation with a protected (re-installed) 5' -monophosphate (5'-P) oligonucleotide, where gray boxes refer to 2'-OMe nucleotides, "X” refers to a protecting group or a component of a chemical entity, and "PNK” refers to polynucleotide kinase.
- 5'-P 5' -monophosphate
- Figure 2B shows an exemplary method for tagging libraries using single-stranded ligation with a protected 3' -OH oligonucleotide, where black boxes attached to -O- refer to a protecting group of the 3' -OH terminus and "LC" refers to liquid chromatographic separation of the protecting group.
- Figure 3 shows an exemplary method for tagging libraries using single-stranded ligation with a 5'-preadenylated (labeled "5'-App”) oligonucleotide (headpiece) with a 3'-terminus that is blocked, e.g., by a chemical entity (labeled "X-3"').
- This method can be used to ligate a 5'-phosphorylated oligonucleotide tag (labeled "Tag A”) to the headpiece and additional tags having a 3' -OH terminus (labeled "Tag B” and "Tag C”) to the complex in the presence of ATP.
- Figures 4A-4E show exemplary complexes, each having a headpiece, a linker, and a small molecule including a scaffold ("S") and diversity nodes A, B, and C.
- the dark gray boxes refer to 2'- OMe nucleotides, and the dotted lines refer to the presence of one or more complementary bases.
- Figures 4A-4B are schematics for complexes having a single-stranded linear oligonucleotide headpiece, where the linker and small molecule are connected to the 3'-terminus ( Figure 4A) or the 5'-terminus ( Figure 4B) of the headpiece.
- Figures 4C-4D are schematics for complexes having a single-stranded hairpin oligonucleotide headpiece, where the linker and small molecule are connected to the internal position ( Figure 4C) or the 3 '-terminus ( Figure 4D) of the headpiece.
- Figure 4E shows an exemplary method for tagging libraries having a hairpin oligonucleotide headpiece, where the star refers to a chemical moiety and "Y" at the 3'4erminus refers to a protecting group. Oligonucleotide tags are labeled 1-4, and the adapter sequence is the black line at the 5 '-terminus.
- Figures 5A-5C show oligonucleotide ligation by T4 RNA ligase or CircLigaseTM ssDNA ligase.
- Figure 5 A is a schematic of the enzymatic ligation reaction.
- the donor oligonucleotide is 5'- phosphorylated and carries a 3 '-fluorescein label, imitating a headpiece with a chemical library at 3' end.
- the acceptor oligonucleotide is not phosphorylated.
- Figure 5B shows gel electrophoresis analysis of a ligation reaction on an 8M urea/ 15% polyacrylamide gel (PAAG).
- PAAG polyacrylamide gel
- SM fluorescently labeled donor
- Product refers to ligation product
- Addenylated donor refers to 5'App-Donor, as described above.
- Figure 5C shows high yield ligation achieved for T4 RNA ligase at high enzyme and
- Figures 6A-6B represent optimization of PEG molecular weight ( Figure 6 A) and concentration
- Figure 6B to achieve maximal ligation yield by T4 RNA ligase. Reaction conditions are as described above for Figures 5A-5C.
- Figure 6A is graph quantifying the electrophoretic analysis of a ligation reaction with MNA/DNA 15mer donor and acceptor tags after incubation for 5 hours or 20 hours with 25% (w/v) PEG having a molecular weight from 300 to 20,000 (20K).
- Figure 6B shows the effect of concentration on ligation after incubation for 18-20 hours in the presence of 5% to 45% (w/v) of PEG4600.
- Figures 7A-7B show a correlation between ligation efficiency by CircLigaseTM ( Figure 7A) and T4 RNA ligase (Figure 7B) and length of the donor or acceptor oligonucleotides.
- Figure 7A depicts a graph quantifying the effect of the acceptor length on ligation yield in the CircLigaseTM ligation reaction.
- Figure 7B depicts a graph and a table quantifying the effect of nucleotide length of the acceptor and donor MNA/DNA tags on single-stranded ligation with T4 RNA ligase.
- FIGS 8A-8B are LC-MS spectra for a MNA/DNA tag before and after phosphorylation. Data are shown for 15mer tag 5'-HO-mUAC GTA TAC GAC TGmG-OH-3' (SEQ ID NO: 13) (at 250 ⁇ ) before ( Figure 8A) and after ( Figure 8B) reaction with T4 polynucleotide kinase (50 units per 5 nmole of tag).
- Figure 9 shows an electrophoretic gel for sequential single-stranded ligation of tags A-C. The 3 '-terminus included fluorescein to represent a library compound (or chemical entity), and the asterisk (*) indicates purification of the ligated product (or complex) prior to phosphorylation.
- Figures 10A-10B show schematics of a "chemically co-reactive pair" reaction between donor and acceptor oligonucleotides resulting in a 5-atom “short” spacer ( Figure 10A) and a 24-atom “long” spacer ( Figure 10B).
- Figures 11A-11E show results of reverse transcription (RT) and PCR analysis of 75mer DNA templates containing a short or a long single spacer, as depicted in Figures 10A-10B.
- Figure 11 A is a schematic of the RT reaction.
- LC-MS spectra of the RT were recorded at both 260 nm and 650 nm for the control 75mer DNA template ( Figure 1 IB), the 75mer DNA template containing a single 5-atom
- Figure 1 IE shows RT-PCR analysis of the control 75mer DNA template ("templ75"), a 75mer DNA template with a 5-atom spacer ("short click"), and a 75mer DNA template with a 24-atom spacer ("long click”).
- Figures 12A-12G show the results of a chemical ligation reaction between a 5'-iodo-modified
- FIG. 12A shows an exemplary schematic of the reaction.
- the 5'-iodo oligonucleotide is labeled with 6-FAM at 3'-terminus, while the 3'-phosphorothioate oligonucleotide is labeled with Cy5 at the 5 '-terminus.
- Figure 12B shows a gel electrophoresis analysis of the ligation reactions in the presence (+spl) or absence (-spl) of a complementary splint.
- CCy5 and CFL indicate visible bands of Cy5 and fluorescein-labeled starting material, respectively.
- Figure 12C shows a time course of the splinted ligation reaction under the above conditions, which was quantified using Cy5 (635 nm) and fluorescein (450 nm) detection.
- Figure 12D shows LC-MS analysis of the ligation of CFL and CCy5 in the absence (top, at 260 nm, 495 nm, and 650 nm) and presence (bottom, at 260 nm, 495 nm, and 650 nm) of a splint, where ligation reactions were incubated for seven days.
- Figure 12E shows LC-MS analysis of the ligation of CFL and CCy5 in the absence a splint (at 260 nm, 495 nm, and 650 nm), where ligation reactions were incubated for eight days.
- Figure 12F shows MS analysis of reaction of CFL oligonucleotide with piperidine, where this reaction was intended to displace iodine.
- Reaction conditions included oligonucleotides at 100 ⁇ , piperidine at 40 mM (400 equivalents) in 100 mM borate buffer, pH 9.5, for 20 hrs at room temperature (left); and oligonucleotides at 400 ⁇ , piperidine at 2 M (4,000 equivalents) in 200 mM borate buffer, pH 9.5, for 2 hrs at 65°C (right).
- Figure 12G shows MS analysis of a splinted ligation reaction of CFL and CCy5 oligonucleotides at 50 ⁇ performed in the presence of 400 equivalents of piperidine in 100 mM borate buffer, pH 9.5, for 20 hrs at room temperature.
- Figures 13A-13C shows the use of modified oligonucleotides to minimize shuffling.
- Figure 13A shows an LC-MS analysis of a single-stranded ligation reaction of a 5'-phosphorylated headpiece ssHP (3,636 Da) and a tag (tag 15; 2,469 Da) having 2'-0 methyl nucleotides.
- the LC-MS analysis showed three peaks: peak 1 for the tag (2,469 Da); peak 2 for the adenylated headpiece (3,965 Da); and peak 3 having two (in some instances three) sub-peaks containing products with molecular weights of 6,089 Da (expected ligation product); 5,769 Da (expected 6,089 Da -320 Da); and 6,409 Da (expected 6,089 Da + 320 Da).
- This mass difference of 320 Da corresponds exactly to either removal or addition of an extra 2'- O-Me C nucleotide.
- Figures 13B-1 to 13B-3 show a non-limiting, proposed mechanism of the nucleotide shuffling, where about 90% of the reaction provides the expected (normal) ligation product and about 10% of the reaction provides aberrant ligation products ("Product -1 nt" and "Product + 1 nt”).
- Figure 13C shows an LC-MS analysis of ligation of headpiece HP-PS with tag 15.
- the headpiece HP-PS has the sequence the headpiece ssHP but includes a phosphorothioate linkage at the 5 '-terminus.
- LC analysis showed three peaks: peak 1 for the tag (2,469), peak 2 for the adenylated headpiece (3,984), and peak 3 for a single ligation product (6,107) with almost no nucleotide shuffling observed. Traces of +/- 320 peaks likely correspond to the oxidative conversion of the phosphorothioate linkage into a native phosphodiester linkage or are due to incomplete sulfurization.
- Figure 14 is a graph showing separation of library members using size exclusion
- FIG 15A is an exemplary schematic showing the chemical ligation of encoding DNA tags using a single chemistry that is not splint-dependent, e.g. 5'-azido/3'-alkynyl.
- the reactive groups are present on the 3' and 5' ends of each tag (Tag A, B, and C), and one of the reactive groups on either end (for example, the 3' end) is protected to prevent the cyclization, polymerization, or wrong-cycle ligation of the tags.
- the cycle of tag ligation includes chemical ligation, followed by deprotection of the remaining functional group to render the growing ligated entity competent for the next cycle of ligation. Each cycle also includes addition of one or more building blocks (BBA, BBB, and BBC, which are encoded by Tag A, B, and C, respectively).
- the chemical ligation process can optionally include addition of a tailpiece.
- Figure 15B is an exemplary schematic showing the chemical ligation of encoding DNA tags using a single chemistry that is splint-dependent.
- the template-dependent nature of this approach reduces the frequency of occurrence of tag polymerization, tag cyclization, as well as of mistagging events.
- this schematic includes tags (Tag A, B, and C) and one or more building blocks encoded by tags (BBA, BBB, and BBC).
- Figure 15C is an exemplary schematic showing the use of a succession of chemically ligated tags as a template for template-dependent polymerization, generating cDNA that is competent for PCR amplification and sequencing, as well as using a template-dependent polymerase capable of reading through the chemically ligated junctions.
- FIG 16A is an exemplary schematic showing the chemical ligation of encoding DNA tags using TIPS-protected alkynyl tags and "click" chemistry.
- Each cycle of library synthesis includes Cu(I)- catalyzed chemical ligation of the TIPS-protected tag to the deprotected alkyne from the previous cycle. After the ligation, the TIPS group is removed (deprotected), thereby activating the alkyne for the next chemical ligation step.
- Figure 16B shows the structure of DMT-succinyl-3'-0-TIPS-propargyl uridine CPG that is used to initiate solid-phase synthesis of oligonucleotides bearing 3 '-O-TIPS-propargyl uridine at the 3'- terminus.
- Figure 16C is an exemplary schematic showing the use of a succession of "click" chemically ligated tags as a template for template-dependent polymerization, generating cDNA that is competent for
- PCR amplification and sequencing as well as using a template-dependent polymerase capable of reading through the "click” chemically ligated junctions.
- Figures 17A-17C show the synthesis of 5'-biotinylated, "single-click" templates Y55 and Y185.
- Figure 17A provides an exemplary schematic.
- Figure 17B and Figure 17C show
- Figures 18A-18C provide an exemplary assay for the "read-through" of a "single-click" template.
- Figure 18A shows a schematic, where FAM-labeled primer is annealed to the biotinylated template and is incubated with the template-dependent polymerase, according to the manufacturer's recommended conditions. The complexes are subsequently incubated with streptavidin beads, washed, eluted with NaOH, and then neutralized. After neutralization the samples are analyzed by LC-MS.
- Figure 18B and Figure 18C show LC-MS data of the Klenow fragment copying of templates Y55 and
- Figures 19A-19D provides the synthesis of 5 '-biotinylated "double-click" template YDC and
- FIGS. 19A and 19B show exemplary schematics for this synthesis.
- Figures 19C and 19D show LC-MS analysis of the YDC and YTC templates respectively.
- Figures 20A-20C provide an exemplary click "read-through” assay using "double-click” and "triple-click” templates.
- Figure 20A is a schematic, where FAM-labeled primer is annealed to the biotinylated template and is incubated with Klenow fragment of E.coli DNA polymerase I according to the manufacturer's recommended reaction conditions. The complexes are incubated with streptavidin beads, washed, eluted with NaOH, and neutralized. After the neutralization, the samples are assayed by LC-MS.
- Figures 20B and 20C show LC-MS data of the Klenow fragment copying of the templates YDC and YTC, respectively.
- Figure 21 is a graph showing the efficiency of the click "read-through” using “single-click”, “double-click” and “triple-click” templates in comparison to a control "no-click” DNA template.
- Figures 22A-22C provide exemplary schematics of chemical ligation with orthogonal chemistry.
- Figure 22A is a schematic of the chemical ligation strategy for DNA encoding tags that (i) utilizes two successive orthogonal chemistries for (ii) available read-through strategies. Each tag contains two orthogonal reactive groups, indicated by differing symbols for the 5'-terminus and the 3'-terminus of each tag. In each successive cycle of chemical ligation, an orthogonal chemistry is used. This strategy reduces the frequency of occurrence of mistagging events and may also be used without the protection of the reactive terminal groups.
- Figure 22B is a schematic of the template-dependent polymerization "read- though" of a template generated by the orthogonal chemical ligation of orthogonal DNA tags to generate cDNA from which the sequence of the tags can be deduced.
- Figure 22C is the same as Figure 22B but includes a self-priming tailpiece, which may be rendered double-stranded by restriction digestion to facilitate strand-separation during PCR amplification.
- FIG 23 is an exemplary schematic showing the chemical ligation strategy for DNA encoding tags that utilizes two specific successive orthogonal chemistries.
- Each tag contains click-reactive and phosphorothioate/iodo-reactive groups.
- Tags bearing orthogonal reactive groups at their 3' and 5' ends cannot polymerize and have a reduced frequency of occurrence of mistagging events. Without wishing to be limited, this approach may eliminate the need for the TIPS-protection of the 3'-alkyne.
- cycle A the 5'-iodo/3'-alkynyl tag is ligated using splint-dependent ligation to the 3'-phosphorothioate headpiece, leaving a reactive 3' alkyne for the next cycle of chemical ligation to a 5'-azido/3'-phosphorothioate tag.
- the orthogonal ligation cycles may be repeated as many times as is desired.
- Figures 24A-24B show the protection and use of 3'-phosphorothioate/5'-iodo groups on DNA tags.
- Figure 24A shows an exemplary schematic for using protecting groups (PG) for these tags.
- Figure 24B shows an exemplary scheme for use of 3'-phosphorothioate/5'-iodo tags to chemically ligate succession of encoding DNA tags that encode a chemical library covalently installed upon the 5'- terminus.
- Figures 25A-25B show the protection and use of 3 '-phosphorothioate groups on DNA tags.
- Figure 25 A shows the scheme for protection of these groups.
- Figure 25B shows the scheme for use of 3'- phosphorothioate/5'-azido and 3'-propargyl/5'-iodo tags to chemically ligate a succession of orthogonal encoding DNA tags that encode a chemical library covalently installed upon the 5 '-terminus.
- the invention features methods of using single-stranded ligation to install oligonucleotide tags onto chemical entity-oligonucleotide complexes.
- This method can be used to create diverse libraries of selectable chemical entities by establishing an encoded relationship between particular tags and particular chemical reactions or building blocks.
- the oligonucleotide tags can be amplified, cloned, sequenced, and correlated by using the established relationship. In particular, reaction conditions that promote single-stranded ligation of tags were identified.
- These conditions include the use of one or more 2 '-substituted nucleotides (e.g., 2'-0-methyl nucleotides or 2'-fluoro nucleotides) within the tags, the use of tags of particular length (e.g., between 5 and 15 nucleotides), the use of one or more enzymes (e.g., RNA ligase and/or DNA ligase), and/or the use of one or more agents during ligation (e.g., poly ethylene glycol and/or a soluble multivalent cation, such as Co(NH 3 ) 6 Cl 3 ).
- 2 '-substituted nucleotides e.g., 2'-0-methyl nucleotides or 2'-fluoro nucleotides
- tags of particular length e.g., between 5 and 15 nucleotides
- one or more enzymes e.g., RNA ligase and/or DNA ligase
- These methods additionally include methods of chemically joining oligonucleotides, such that the sequence of the joined oligonucleotide product may be utilized as a template for a template-dependent polymerase reaction. Methods of creating and tagging libraries of these complexes are described in detail below.
- This invention features a method for operatively linking oligonucleotide tags with chemical entities, such that encoding relationships may be established between the sequence of the tag and the structural units (or building blocks) of the chemical entity.
- identity and/or history of a chemical entity can be inferred from the sequence of bases in the oligonucleotide.
- a library including diverse chemical entities or members e.g., small molecules or peptides
- these methods include the use of a headpiece, which has at least one functional group that may be elaborated chemically and at least one functional group to which a single-stranded oligonucleotide may be bound (or ligated). Binding can be effectuated by any useful means, such as by enzymatic binding (e.g., ligation with one or more of an RNA ligase and/or a DNA ligase) or by chemical binding (e.g., by a substitution reaction between two functional groups, such as a nucleophile and a leaving group).
- enzymatic binding e.g., ligation with one or more of an RNA ligase and/or a DNA ligase
- chemical binding e.g., by a substitution reaction between two functional groups, such as a nucleophile and a leaving group.
- a solution containing the headpiece can be divided into multiple aliquots and then placed into a multiplicity of physically separate compartments, such as the wells of a multiwell plate. Generally, this is the "split" step. Within each compartment or well, successive chemical reaction and ligation steps are performed with a single-stranded tag within each aliquot. The relationship between the chemical reaction conditions and the sequence of the single- stranded tag are recorded. The reaction and ligation steps may be performed in any order. Then, the reacted and ligated aliquots are combined or "pooled,” and optionally purification may be performed at this point. These split and pool steps can be optionally repeated.
- the library can be tested and/or selected for a particular characteristic or function, as described herein.
- the mixture of tagged chemical entities can be separated into at least two populations, where the first population binds to a particular biological target and the second population does not.
- the first population can then be selectively captured (e.g., by eluting on a column providing the target of interest or by incubating the aliquot with the target of interest) and, optionally, further analyzed or tested, such as with optional washing, purification, negative selection, positive selection, or separation steps.
- the chemical histories of one or more members (or chemical entities) within the selected population can be determined by the sequence of the operatively linked oligonucleotide.
- this method can identify the individual members of the library with the selected characteristic (e.g., an increased tendency to bind to the target protein and thereby elicit a therapeutic effect).
- candidate therapeutic compounds may then be prepared by synthesizing the identified library members with or without their associated oligonucleotide tags.
- Figures 1-3 provide various exemplary methods for tagging libraries using single-stranded ligation with a headpiece, where tags can be ligated on the 5 '-terminus or the 3 '-terminus of the headpiece. To control the order in which the tags are ligated and to reduce side reactions, these methods ensure that only one reactive 5 '-terminus and one reactive 3 '-terminus are present during ligation.
- these exemplary methods use 2 '-substituted nucleotides (e.g., mixed 2'-deoxy/2'-0-methyl nucleotides) in the tags, and these tags act as templates for a DNA- or RNA-dependent polymerase capable of polymerizing nucleotides in a template-dependent fashion.
- 2 '-substituted nucleotides e.g., mixed 2'-deoxy/2'-0-methyl nucleotides
- the use of one or more 2 '-substituted nucleotides within a tag could promote ligation by RNA ligase by more closely resembling RNA, while preserving both the physical and chemical robustness of the recording medium as well as the ability to extract sequence information using template-dependent polymerization.
- Figure 1 provides an exemplary method for reducing side reactions, where the ligated complex and tags are designed to avoid unwanted reactions between reactive 3'-OH and 5 '-monophosphate ("5'- P") groups.
- this scheme depicts the phosphorylation-ligation cycle approach.
- ligation only one 3' -OH group (in the tag) and one 5'-P group (in the headpiece) are available, and, thus, only one ligation event is possible.
- a 5' -OH group is formed in the complex, and this group can be converted into a 5'-P for adding subsequent oligonucleotide tags.
- the 3'-terminus of the complex is blocked by X, which can be a protecting group or a component of a chemical entity (e.g., optionally including a linker that acts as a spacer between the chemical entity and the headpiece).
- the exemplary method includes ligation of building block tag 1 ("tag 1") to the 5 '-terminus of the headpiece, thereby creating a complex, and performing successive ligations to the 5 '-terminus of the complex.
- the reactive 5 '-terminus is a phosphate group on the complex
- the reactive 3 '-terminus is a hydroxyl group on the tags.
- Separation can be accomplished by any useful method (e.g., by chromatographic or electrophoretic separation of ligated and non-ligated products or by precipitation of a reagent). Then, the ligated complex is exposed to an agent (e.g., a polynucleotide kinase or a chemical phosphorylating agent) to form a phosphate group on the 5 '-terminus of the complex.
- an agent e.g., a polynucleotide kinase or a chemical phosphorylating agent
- the method includes binding successive tags from the 3 '-terminus of the preceding ligated complex.
- the ligated complex lacks a reactive 3' -OH group immediately after the ligation step but contains a group that can be converted into a 3' -OH group (e.g., by release of a protecting group).
- Figure 2A provides a schematic showing an exemplary method for tagging the 3 '-terminus of a complex
- Figure 2B provides an exemplary reaction scheme for a protected 3'- terminus that contains convertible 3' -OH group upon release of the 3 '-linked protecting group.
- building block tag 1 (“tag 1") has a 3 '-protected group.
- the exemplary method includes ligation of the tag to the 3 '-terminus of the headpiece, thereby creating a complex. Successive ligations are performed to the 3'-terminus of the complex.
- the reactive 5'-terminus is a phosphate group on the tag
- the reactive 3 '-terminus is a hydroxyl group on the complex.
- the ligated complex is deprotected (e.g., by the addition of a hydrolyzing agent) to release the 3 '-protecting group.
- the method includes binding successive tags by using a 5'- preadenylated (5'-App) oligonucleotide and a ligase (e.g., T4 RNA ligase).
- a ligase e.g., T4 RNA ligase
- T4 RNA ligase will use the ATP cofactor to form an adenylated intermediate prior to ligation.
- T4 RNA ligase will only ligate preadenylated oligonucleotides, and possible side reactions with 5'-P oligonucleotides will not occur.
- single-stranded ligation with reduced side reactions can be performed with a chemically synthesized 5'-App oligonucleotide in the presence of 5'- monophosphorylated tag, where the 5'-App oligonucleotide can be ligated to a headpiece prior to tagging or to a complex formed after multiple rounds of tagging.
- Figure 3 provides a schematic showing an exemplary method for tagging the 5 '-terminus of a preadenylated headpiece.
- Adenylation of the donor nucleotide at the 5 '-phosphate group is the first step in the ligation reaction, and this reaction generally requires one molecule of ATP.
- the 3' -OH group of the acceptor oligonucleotide reacts with the adenylated donor and forms a diester bond between two oligonucleotides, thus releasing one AMP molecule.
- the chemically adenylated 5'- phosphate group of the donor oligonucleotide imitates a product of the first step of the ligation reaction and can be ligated to the second oligonucleotide in the absence of ATP.
- a 5'- App headpiece is ligated to the 3' -OH group of a 5'-phosphorylated oligonucleotide tag (labeled "Tag A"). Due to the presence of the adenylated 5 '-terminus of the oligonucleotide, ligation can occur in the absence of ATP. Under these conditions, the 5 '-phosphate group of Tag A does not serve as a ligation donor.
- Building block Tag B can be ligated by providing a nucleotide having a 3' -OH terminus (labeled "Tag B") in the presence of ATP, and additional tags (labeled "Tag C”) can be included.
- the 3'-terminus of the headpiece can be blocked with any protecting group (e.g., an irreversible protecting group, such as ddN, or a reversible protecting group).
- the method includes ligation of the tag to the 5 '-terminus of the headpiece in the absence of ATP, thereby creating a complex. Successive ligations are performed to the 5 '-terminus of the complex in the presence of ATP.
- This method can be modified in order to perform successive ligation to the 3'-terminus of a complex.
- the method can include the use of a 5'-preadenylated tag and a headpiece having a reactive 3'- OH terminus. This method may further require blocking the 3 '-terminus of the tag to avoid cross- reactions between tags, such as the method described above and in Figure 2.
- the general method provided in Figure 3 can be modified by replacing the primer with a headpiece.
- the headpiece has to be adenylated chemically at the 5 '-terminus, and Tag A is phosphorylated at 5 '-terminus. Ligation of this phosphorylated Tag A to the adenylated headpiece occurs in the same standard conditions, described herein, but omitting ATP. By using this ligation condition, the ligation of phosphorylated 5 ' terminus can be prevented. In the next step, ligation of Tag B requires that this tag have a free hydroxyl group at 5'-terminus (i.e., non-phosphorylated).
- Successive ligation reactions can be performed in the presence of ATP, followed by phosphorylation of the 5 '-terminus of the resulting oligonucleotide if further extension of the tags (e.g., Tag C in Figure 3) is desired.
- tags e.g., Tag C in Figure 3
- the methods described herein can include any number of optional steps to diversify the library or to interrogate the members of the library.
- any tagging method described herein e.g., as in Figures 1- 3
- successive "n" number of tags can be added with additional "n” number of ligation, separation, and/or phosphorylation steps.
- Exemplary optional steps include restriction of library members using one or more restriction endonucleases; ligation of one or more adapter sequences to one or both of the library termini, e.g., such as one or more adapter sequences to provide a priming sequence for amplification and sequencing or to provide a label, such as biotin, for immobilization of the sequence; reverse-transcription or transcription, optionally followed by reverse-transcription, of the assembled tags in the complex using a reverse transcriptase, transcriptase, or another template-dependent polymerase; amplification of the assembled tags in the complex using, e.g., PCR; generation of clonal isolates of one or more populations of assembled tags in the complex, e.g., by use of bacterial transformation, emulsion formation, dilution, surface capture techniques, etc.; amplification of clonal isolates of one or more populations of assembled tag in the complex, e.g., by using clonal isolates as templates for template-dependent polymerization
- the method comprises identifying a small drug-like library member that binds or inactivates a protein of therapeutic interest.
- a sequence of chemical reactions is designed, and a set of building blocks is chosen so that the reaction of the chosen building blocks under the defined chemical conditions will generate a combinatorial plurality of molecules (or a library of molecules), where one or more molecules may have utility as a therapeutic agent for a particular protein.
- the chemical reactions and building blocks are chosen to create a library having structural groups commonly present in kinase inhibitors.
- the tags encode the chemical history of the library member and, in each case, a collection of chemical possibilities may be represented by any particular tag combination.
- the library of chemical entities, or a portion thereof is contacted with a biological target under conditions suitable for at least one member of the library to bind to the target, followed by removal of library members that do not bind to the target, and analyzing the one or more oligonucleotide tags associated with them.
- This method can optionally include amplifying the tags by methods known in the art.
- Exemplary biological targets include enzymes (e.g., kinases, phosphatases, methylases, demethylases, proteases, and DNA repair enzymes), proteins involved in proteimprotein interactions (e.g., ligands for receptors), receptor targets (e.g., GPCRs and RTKs), ion channels, bacteria, viruses, parasites, DNA, RNA, prions, and carbohydrates.
- enzymes e.g., kinases, phosphatases, methylases, demethylases, proteases, and DNA repair enzymes
- proteins involved in proteimprotein interactions e.g., ligands for receptors
- receptor targets e.g., GPCRs and RTKs
- ion channels e.g., bacteria, viruses, parasites, DNA, RNA, prions, and carbohydrates.
- the chemical entities that bind to a target are not subjected to amplification but are analyzed directly.
- Exemplary methods of analysis include microarray analysis, including evanescent resonance photonic crystal analysis; bead-based methods for deconvoluting tags (e.g., by using his-tags); label-free photonic crystal biosensor analysis (e.g., a BIND® Reader from SRU Biosystems, Inc., Woburn, MA); or hybridization-based approaches (e.g. by using arrays of immobilized oligonucleotides complementary to sequences present in the library of tags).
- microarray analysis including evanescent resonance photonic crystal analysis; bead-based methods for deconvoluting tags (e.g., by using his-tags); label-free photonic crystal biosensor analysis (e.g., a BIND® Reader from SRU Biosystems, Inc., Woburn, MA); or hybridization-based approaches (e.g. by using arrays of immobilized oligonucleotides complementary to sequence
- any of the binding steps described herein for tagging encoded libraries can be modified to include one or more of enzymatic ligation and/or chemical ligation techniques.
- Exemplary ligation techniques include enzyme ligation, such as use of one of more RNA ligases and/or DNA ligases; and chemical ligation, such as use of chemically co-reactive pairs (e.g., a pair including optionally substituted alkynyl and azido functional groups).
- one or more libraries can be combined in a split-and-mix step.
- the library member may contain one or more library-identifying sequences, such as in a library-identifying tag, in a ligated building block tag, or as part of the headpiece sequence, as described herein.
- the length of one or more building block tags can be reduced, such as to a length that is as short as possible to encode each split size.
- the tags can be less than 20 nucleotides (e.g., less than 19 nucleotides, less than 18 nucleotides, less than 17 nucleotides, less than 16 nucleotides, less than 15 nucleotides, less than 14 nucleotides, less than 13 nucleotides, less than 12 nucleotides, less than 11 nucleotides, less than 10 nucleotides, less than 9 nucleotides, less than 8 nucleotides, or less than 7 nucleotides).
- shorter tags e.g, about 10 nucleotides or shorter can be used for tag ligation.
- Constant mass strategies can also be used, which could aid in analysis during library synthesis.
- constant mass tag sets could permit the recognition of all single error occurences (e.g., errors arising from misreading a sequence or from chemical or enzymatic ligation of a tag) and most multiple error occurrences.
- the relationship between the length of a constant mass single-stranded tag set and encoding ability e.g., minimum lengths to support specific building block split sizes or library identities, etc.
- use of constant mass tag sets could be used to provide beneficial encoding ability, while maintaining error recognition during library formation.
- the headpiece can be used not only to link the chemical moiety and a tag but to also encode for the identity of a particular library or for a particular step.
- the headpiece can encode information, e.g., a plurality of headpieces that encode the first split(s) or the identity of the library, such as by using a particular sequence related to a specific library.
- primer binding regions from the library of DNA-encoded chemical entities can be excluded during the selection step(s). Then, these regions can be added after selection by, e.g., single-stranded ligation.
- One exemplary strategy would include providing a chemical entity at the 5 '-terminus of a encoding oligonucleotide, selecting a particular chemical entity based on any useful particular characteristic or function, and ligating a tailpiece oligonucleotide to the 3 '-terminus of the encoding oligonucleotide that includes a primer binding sequence and may optionally contain one or more tags, e.g.
- This primer binding sequence could then be used to initiate template-dependent polymerization to generate cDNA (or cRNA) that is complementary to the selected library member.
- the cDNA or cRNA would then be ligated at its 3'- terminus to an oligonucleotide that contains a primer binding sequence and, now that the encoding information is flanked on both sides by primer binding sequences, the oligonucleotide may be sequenced and/or amplified using established approaches, such as any described herein. Mass may further be minimized by omitting or reducing the size of one or more constant sequences that separate encoding tags.
- Single-stranded ligation requires no complementary relationship between the ends to be ligated or between these ends and a splint. Therefore, no fixed sequence is required to support enzymatic ligation. Short fixed regions between tags may be useful for informatic parsing of tags or other in silico deconvolution processes.
- oligonucleotide tags described herein can be used to encode any useful information, such as a molecule, a portion of a chemical entity, the addition of a component (e.g., a scaffold or a building block), a headpiece in the library, the identity of the library, the use of one or more library members (e.g., use of the members in an aliquot of a library), and/or the origin of a library member (e.g., by use of an origin sequence).
- any sequence in an oligonucleotide can be used to encode any information.
- one oligonucleotide sequence can serve more than one purpose, such as to encode two or more types of information or to provide a starting oligonucleotide that also encodes for one or more types of information.
- the first building block tag can encode for the addition of a first building block, as well as for the identification of the library.
- a headpiece can be used to provide a starting oligonucleotide that operatively links a chemical entity to a building block tag, where the headpiece additionally includes a sequence that encodes for the identity of the library (i.e., the library- identifying sequence).
- any of the information described herein can be encoded in separate oligonucleotide tags or can be combined and encoded in the same oligonucleotide sequence (e.g., an oligonucleotide tag, such as a building block tag, or a headpiece).
- a building block sequence encodes for the identity of a building block and/or the type of binding reaction conducted with a building block.
- This building block sequence is included in a building block tag, where the tag can optionally include one or more types of sequence described below (e.g., a library- identifying sequence, a use sequence, and/or an origin sequence).
- a libraiy-identifying sequence encodes for the identity of a particular library.
- a library member may contain one or more library-identifying sequences, such as in a library-identifying tag (i.e., an oligonucleotide including a library-identifying sequence), in a ligated building block tag, in a part of the headpiece sequence, or in a tailpiece sequence.
- library-identifying sequences can be used to deduce encoding relationships, where the sequence of the tag is translated and correlated with chemical (synthesis) history information. Accordingly, these library- identifying sequences permit the mixing of two or more libraries together for selection, amplification, purification, sequencing, etc.
- a use sequence encodes the history (i.e., use) of one or more library members in an individual aliquot of a library. For example, separate aliquots may be treated with different reaction conditions, building blocks, and/or selection steps. In particular, this sequence may be used to identify such aliquots and deduce their history (use) and thereby permit the mixing together of aliquots of the same library with different histories (uses) (e.g., distinct selection experiments) for the purposes of the mixing together of samples together for selection, amplification, purification, sequencing, etc.
- use sequences can be included in a headpiece, a tailpiece, a building block tag, a use tag (i.e., an oligonucleotide including a use sequence), or any other tag described herein (e.g., a library-identifying tag or an origin tag).
- a use tag i.e., an oligonucleotide including a use sequence
- any other tag described herein e.g., a library-identifying tag or an origin tag.
- An origin sequence is a degenerate (random) oligonucleotide sequence of any useful length (e.g., about six oligonucleotides) that encodes for the origin of the library member.
- This sequence serves to stochastically subdivide library members that are otherwise identical in all respects into entities distinguishable by sequence information, such that observations of amplification products derived from unique progenitor templates (e.g., selected library members) can be distinguished from observations of multiple amplification products derived from the same progenitor template (e.g., a selected library member).
- each library member can include a different origin sequence, such as in an origin tag.
- selected library members can be amplified to produce amplification products, and the portion of the library member expected to include the origin sequence (e.g., in the origin tag) can be observed and compared with the origin sequence in each of the other library members.
- the origin sequences are degenerate, each
- amplification product of each library member should have a different origin sequence.
- an observation of the same origin sequence in the amplification product could indicate a source of error, such as an amplification error or a cyclization error in the sequence that produces repeated sequences, and the starting point or source of these errors can be traced by observing the origin sequence at each step (e.g., at each selection step or amplification step) of using the library.
- These origin sequences can be included in a headpiece, a tailpiece, a building block tag, an origin tag (i.e., an oligonucleotide including an origin sequence), or any other tag described herein (e.g., a library-identifying tag or a use tag).
- the headpiece can include one or more of a building block sequence, a library-identifying sequence, a use sequence, or an origin sequence.
- the tailpiece can include one or more of a library-identifying sequence, a use sequence, or an origin sequence.
- sequences can include any modification described herein for oligonucleotides, such as one or more modifications that promote solubility in organic solvents (e.g., any described herein, such as for the headpiece), that provide an analog of the natural phosphodiester linkage (e.g., a phosphorothioate analog), or that provide one or more non-natural oligonucleotides (e.g., 2 '-substituted nucleotides, such as 2'-0-methylated nucleotides and 2'-fluoro nucleotides, or any described herein).
- modifications that promote solubility in organic solvents e.g., any described herein, such as for the headpiece
- an analog of the natural phosphodiester linkage e.g., a phosphorothioate analog
- non-natural oligonucleotides e.g., 2 '-substituted nucleotides, such as 2'-0-methylated nucle
- sequences can include any characteristics described herein for oligonucleotides.
- these sequences can be included in tag that is less than 20 nucleotides (e.g., as described herein).
- the tags including one or more of these sequences have about the same mass (e.g., each tag has a mass that is about +/- 10% from the average mass between two or more tags); lack a primer binding (e.g., constant) region; lack a constant region; or have a constant region of reduced length (e.g., a length less than 30 nucleotides, less than 25 nucleotides, less than 20 nucleotides, less than 19 nucleotides, less than 18 nucleotides, less than 17 nucleotides, less than 16 nucleotides, less than 15 nucleotides, less than 14 nucleotides, less than 13 nucleotides, less than 12 nucleotides, less than 11 nucleotides, less than 10 nucleotides
- Sequencing strategies for libraries and oligonucleotides of this length may optionally include concatenation or catenation strategies to increase read fidelity or sequencing depth, respectively.
- the selection of encoded libraries that lack primer binding regions has been described in the literature for SELEX, such as described in Jarosch et al., Nucleic Acids Res. 34: e86 (2006), which is incorporated herein by reference.
- a library member can be modified (e.g., after a selection step) to include a first adapter sequence on the 5 '-terminus of the complex and a second adapter sequence on the 3 '-terminus of the complex, where the first sequence is substantially complementary to the second sequence and result in forming a duplex.
- two fixed dangling nucleotides e.g., CC
- the first adapter sequence is 5'-
- the headpiece operatively links each chemical entity to its encoding
- the headpiece is a starting oligonucleotide having two functional groups that can be further derivatized, where the first functional group operatively links the chemical entity (or a component thereof) to the headpiece and the second functional group operatively links one or more tags to the headpiece.
- a linker can optionally be used as a spacer between the headpiece and the chemical entity.
- the functional groups of the headpiece can be used to form a covalent bond with a component of the chemical entity and another covalent bond with a tag.
- the component can be any part of the small molecule, such as a scaffold having diversity nodes or a building block.
- the headpiece can be derivatized to provide a linker (i.e., a spacer separating the headpiece from the small molecule to be formed in the library) terminating in a functional group (e.g., a hydroxyl, amine, carboxyl, sulfhydryl, alkynyl, azido, or phosphate group), which is used to form the covalent linkage with a component of the chemical entity.
- a linker i.e., a spacer separating the headpiece from the small molecule to be formed in the library
- a functional group e.g., a hydroxyl, amine, carboxyl, sulfhydryl, alkynyl, azido, or
- the linker can be attached to the 5 '-terminus, at one of the internal positions, or to the 3 '-terminus of the headpiece.
- the linker can be operatively linked to a derivatized base (e.g., the C5 position of uridine) or placed internally within the oligonucleotide using standard techniques known in the art. Exemplary linkers are described herein.
- the headpiece can have any useful structure.
- the headpiece can be, e.g., 1 to 100 nucleotides in length, preferably 5 to 20 nucleotides in length, and most preferably 5 to 15 nucleotides in length.
- the headpiece can be single-stranded or double-stranded and can consist of natural or modified nucleotides, as described herein. Particular exemplary embodiments of the headpiece are described in Figures 4A-4D.
- the chemical moiety can be operatively linked to the 3 '-terminus ( Figure 4 A) or 5 '-terminus ( Figure 4B) of the headpiece.
- the headpiece includes a hairpin structure formed by complementary bases within the sequence.
- the chemical moiety can be operatively linked to the internal position ( Figure 4C), the 3 '-terminus ( Figure 4D), or the 5 '-terminus of the headpiece.
- the headpiece includes a non-complementary sequence on the 5'- or 3'- terminus that allows for binding an oligonucleotide tag by polymerization, enzymatic ligation, or chemical reaction.
- the exemplary headpiece allows for ligation of oligonucleotide tags (labeled 1 -4), and the method includes purification and phosphorylation steps.
- an additional adapter sequence can be added to the 5 '-terminus of tag 4.
- Exemplary adapter sequences include a primer binding sequence or a sequence having a label (e.g., biotin).
- a mix-and-split strategy may be employed during the oligonucleotide synthesis step to create the necessary number of tags.
- mix-and-split strategies for DNA synthesis are known in the art.
- the resultant library members can be amplified by PCR following selection for binding entities versus a target(s) of interest.
- the headpiece or the complex can optionally include one or more primer binding sequences.
- the headpiece has a sequence in the loop region of the hairpin that serves as a primer binding region for amplification, where the primer binding region has a higher melting temperature for its complementary primer (e.g., which can include flanking identifier regions) than for a sequence in the headpiece.
- the complex includes two primer binding sequences (e.g., to enable a PCR reaction) on either side of one or more tags that encode one or more building blocks.
- the headpiece may contain one primer binding sequence on the 5'- or 3 '-terminus.
- the headpiece is a hairpin
- the loop region forms a primer binding site or the primer binding site is introduced through hybridization of an oligonucleotide to the headpiece on the 3' side of the loop.
- a primer oligonucleotide containing a region homologous to the 3 '-terminus of the headpiece and carrying a primer binding region on its 5 '-terminus (e.g., to enable a PCR reaction) may be hybridized to the headpiece and may contain a tag that encodes a building block or the addition of a building block.
- the primer oligonucleotide may contain additional information, such as a region of randomized nucleotides, e.g., 2 to 16 nucleotides in length, which is included for bioinformatics analysis.
- the headpiece can optionally include a hairpin structure, where this structure can be achieved by any useful method.
- the headpiece can include complementary bases that form
- the headpiece can include modified or substituted nucleotides that can form higher affinity duplex formations compared to unmodified nucleotides, such modified or substituted nucleotides being known in the art.
- the headpiece includes one or more crosslinked bases to form the hairpin structure. For example, bases within a single strand or bases in different double strands can be crosslinked, e.g., by using psoralen.
- the headpiece or complex can optionally include one or more labels that allow for detection.
- the headpiece, one or more oligonucleotide tags, and/or one or more primer sequences can include an isotope, a radioimaging agent, a marker, a tracer, a fluorescent label (e.g., rhodamine or fluorescein), a chemiluminescent label, a quantum dot, and a reporter molecule (e.g., biotin or a his-tag).
- the headpiece or tag may be modified to support solubility in semi-, reduced-, or non-aqueous (e.g., organic) conditions.
- Nucleotide bases of the headpiece or tag can be rendered more hydrophobic by modifying, for example, the C5 positions of T or C bases with aliphatic chains without significantly disrupting their ability to hydrogen bond to their complementary bases.
- Exemplary modified or substituted nucleotides are 5'-dimethoxytrityl-N4-diisobutylaminomethylidene-5- (l-propynyl)-2'-deoxycytidine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5'- dimethoxytrityl-5-(l-propynyl)-2'-deoxyuridine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 5'-dimethoxytrityl-5-fluoro-2'-deoxyuridine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; and 5 ' -dimethoxytrityl-5 -(pyren- 1 -yl-ethynyl)-2 '
- the headpiece oligonucleotide can be interspersed with modifications that promote solubility in organic solvents.
- azobenzene phosphoramidite can introduce a hydrophobic moiety into the headpiece design.
- Such insertions of hydrophobic amidites into the headpiece can occur anywhere in the molecule.
- the insertion cannot interfere with subsequent tagging using additional DNA tags during the library synthesis or ensuing PCR once a selection is complete or microarray analysis, if used for tag deconvolution.
- Such additions to the headpiece design described herein would render the headpiece soluble in, for example, 15%, 25%, 30%, 50%, 75%, 90 %, 95%, 98%, 99%, or 100% organic solvent.
- hydrophobic residues into the headpiece design allows for improved solubility in semi- or non-aqueous (e.g., organic) conditions, while rendering the headpiece competent for oligonucleotide tagging.
- DNA tags that are subsequently introduced into the library can also be modified at the C5 position of T or C bases such that they also render the library more hydrophobic and soluble in organic solvents for subsequent steps of library synthesis.
- the headpiece and the first building block tag can be the same entity, i.e., a plurality of headpiece-tag entities can be constructed that all share common parts (e.g., a primer binding region) and all differ in another part (e.g., encoding region). These may be utilized in the "split" step and pooled after the event they are encoding has occurred.
- the headpiece can encode information, e.g., by including a sequence that encodes the first split(s) step or a sequence that encodes the identity of the library, such as by using a particular sequence related to a specific library. Enzymatic ligation and chemical ligation techniques
- any of the binding steps described herein can include any useful ligation techniques, such as enzyme ligation and/or chemical ligation. These binding steps can include the addition of one or more building block tags to the headpiece or complex; the addition of a linker to the headpiece; and the addition of one or more scaffolds or building blocks to the headpiece or complex.
- oligonucleotide provide a resultant product that can be transcribed and/or reverse transcribed to allow for decoding of the library or for template-dependent polymerization with one or more DNA or RNA polymerases.
- enzyme ligation produces an oligonucleotide having a native phosphodiester bond that can be transcribed and/or reverse transcribed.
- exemplary methods of enzyme ligation include the use of one or more RNA or DNA ligases, such as T4 RNA ligase, T4 DNA ligase, CircLigaseTM ssDNA ligase, CircLigaseTM II ssDNA ligase, and ThermoPhageTM ssDNA ligase
- Chemical ligation can also be used to produce oligonucleotides capable of being transcribed or reverse transcribed.
- One benefit of chemical ligation is that solid phase synthesis of such
- oligonucleotides can be optimized to support efficient ligation yield. However, the efficacy of a chemical ligation technique to provide oligonucleotides capable of being transcribed or reverse transcribed may need to be tested. This efficacy can be tested by any useful method, such as liquid chromatography-mass spectrometry, RT-PCR analysis, and/or PCR analysis. Examples of these methods are provided in Example 5.
- chemical ligation includes the use of one or more chemically co- reactive pairs to provide a spacer that can be transcribed or reverse transcribed.
- reactions suitable for chemically co-reactive pairs are preferred candidates for the cyclization process (Kolb et al., Angew. Chem. Int. Ed., 40:2004-2021 (2001); Van der Eycken et al, QSAR Comb. ScL, 26:1115-1326 (2007)).
- Exemplary chemically co-reactive pairs are a pair including an optionally substituted alkynyl group and an optionally substituted azido group to form a triazole spacer via a Huisgen 1,3-dipolar cycloaddition reaction; an optionally substituted diene having a 4 ⁇ electron system (e.g., an optionally substituted 1 ,3-unsaturated compound, such as optionally substituted 1,3-butadiene, l-methoxy-3- trimethylsilyloxy- 1 ,3 -butadiene, cyclopentadiene, cyclohexadiene, or furan) and an optionally substituted dienophile or an optionally substituted heterodienophile having a 2 ⁇ electron system (e.g., an optionally substituted alkenyl group or an optionally substituted alkynyl group) to form a cycloalkenyl spacer via a Diels-Alder reaction; a nucleophile (e.g
- chemical ligation includes introducing an analog of the phosphodiester bond, e.g., for post-selection PCR analysis and sequencing.
- exemplary analogs of a phosphodiester include a phosphorothioate linkage (e.g., as introduced by use of a phosphorothioate group and a leaving group, such as an iodo group), a phosphoramide linkage, or a phosphorodithioate linkage (e.g., as introduced by use of a phosphorodithioate group and a leaving group, such as an iodo group).
- the invention also features one or more reaction conditions that promote enzymatic or chemical ligation between the headpiece and a tag or between two tags.
- reaction conditions include using modified nucleotides within the tag, as described herein; using donor tags and acceptor tags having different lengths and varying the concentration of the tags; using different types of ligases, as well as combinations thereof (e.g., CircLigaseTM DNA ligase and/or T4 RNA ligase), and varying their concentration; using poly ethylene glycols (PEGs) having different molecular weights and varying their concentration; use of non-PEG crowding agents (e.g., betaine or bovine serum albumin); varying the temperature and duration for ligation; varying the concentration of various agents, including ATP, Co(NH 3 ) 6 Cl 3 , and yeast inorganic pyrophosphate; using enzymatically or chemically phosphorylated oligonucleotide tags; using 3'-protected tags; and using preadeny
- the headpiece and/or tags can include one or more modified or substituted nucleotides.
- the headpiece and/or tags include one or more modified or substituted nucleotides that promote enzymatic ligation, such as 2'-0-methyl nucleotides (e.g., 2'-0-methyl guanine or 2'-0-methyl uracil), 2'-fluoro nucleotides, or any other modified nucleotides that are utilized as a substrate for ligation.
- the headpiece and/or tags are modified to include one or more chemically reactive groups to support chemical ligation (e.g. an optionally substituted alkynyl group and an optionally substituted azido group).
- the tag oligonucleotides are functionalized at both termini with chemically reactive groups, and, optionally, one of these termini is protected, such that the groups may be addressed independently and side-reactions may be reduced (e.g., reduced polymerization side-reactions).
- Enzymatic ligation can include one or more ligases.
- Exemplary ligases include CircLigaseTM ssDNA ligase (EPICENTRE Biotechnologies, Madison, WI), CircLigaseTM II ssDNA ligase (also from EPICENTRE Biotechnologies), ThermoPhageTM ssDNA ligase (Prokazyme Ltd., Reykjavik, Iceland), T4 RNA ligase, and T4 DNA ligase.
- ligation includes the use of an RNA ligase or a combination of an RNA ligase and a DNA ligase.
- Ligation can further include one or more soluble multivalent cations, such as Co(NH 3 ) 6 Cl 3 , in combination with one or more ligases.
- the complex Before or after the ligation step, the complex can be purified for three reasons. First, the complex can be purified to remove unreacted headpiece or tags that may result in cross-reactions and introduce "noise" into the encoding process. Second, the complex can be purified to remove any reagents or unreacted starting material that can inhibit or lower the ligation activity of a ligase. For example, phosphate may result in lowered ligation activity. Third, entities that are introduced into a chemical or ligation step may need to be removed to enable the subsequent chemical or ligation step. Methods of purifying the complex are described herein.
- Enzymatic and chemical ligation can include poly ethylene glycol having an average molecular weight of more than 300 Daltons (e.g., more than 600 Daltons, 3,000 Daltons, 4,000 Daltons, or 4,500 Daltons).
- the poly ethylene glycol has an average molecular weight from about 3,000 Daltons to 9,000 Daltons (e.g., from 3,000 Daltons to 8,000 Daltons, from 3,000 Daltons to 7,000 Daltons, from 3,000 Daltons to 6,000 Daltons, and from 3,000 Daltons to 5,000 Daltons).
- the poly ethylene glycol has an average molecular weight from about 3,000 Daltons to about 6,000 Daltons (e.g., from 3,300 Daltons to 4,500 Daltons, from 3,300 Daltons to 5,000 Daltons, from 3,300 Daltons to 5,500 Daltons, from 3,300 Daltons to 6,000 Daltons, from 3,500 Daltons to 4,500 Daltons, from 3,500 Daltons to 5,000 Daltons, from 3,500 Daltons to 5,500 Daltons, and from 3,500 Daltons to 6,000 Daltons, such as 4,600 Daltons).
- Poly ethylene glycol can be present in any useful amount, such as from about 25% (w/v) to about 35% (w/v), such as 30% (w/v).
- the building block tags are installed by ligation of a single-stranded oligonucleotide to a single-stranded oligonucleotide using the ligation protocol outlined below:
- Headpiece 25 ⁇ (5' terminus: 5'-monophospho/2'-OMe G,
- Yeast Inorganic Pyrophosphatase 0.0025 units/ ⁇
- the protocol includes incubation at 37°C for 20 hours.
- higher concentration of headpiece, tags, and/or ligase may be used, and such modifications to these concentrations would be apparent to those skilled in the art.
- the methods of the invention can be used to synthesize a library having a diverse number of chemical entities that are encoded by oligonucleotide tags. Examples of building blocks and encoding DNA tags are found in U.S. Patent Application Publication No. 2007/0224607, hereby incorporated by reference.
- Each chemical entity is formed from one or more building blocks and optionally a scaffold.
- the scaffold serves to provide one or more diversity nodes in a particular geometry (e.g., a triazine to provide three nodes spatially arranged around a heteroaryl ring or a linear geometry).
- the building blocks and their encoding tags can be added directly or indirectly (e.g., via a linker) to the headpiece to form a complex.
- the headpiece includes a linker
- the building block or scaffold is added to the end of the linker.
- the linker is absent, the building block can be added directly to the headpiece or the building block itself can include a linker that reacts with a functional group of the headpiece. Exemplary linkers and headpieces are described herein.
- the scaffold can be added in any useful way.
- the scaffold can be added to the end of the linker or the headpiece, and successive building blocks can be added to the available diversity nodes of the scaffold.
- building block A n is first added to the linker or the headpiece, and then the diversity node of scaffold S is reacted with a functional group in building block A n .
- Oligonucleotide tags encoding a particular scaffold can optionally be added to the headpiece or the complex.
- S is added to the complex in n reaction vessels, where n is an integer more than one, and tag S n (i.e., tag Si, S 2 , ... S n .i, S n ) is bound to the functional group of the complex.
- Building blocks can be added in multiple, synthetic steps. For example, an aliquot of the headpiece, optionally having an attached linker, is separated into n reaction vessels, where n is an integer of two or greater.
- building block A is added to each n reaction vessel (i.e., building block A,, A 2 , ... A n .i, A n is added to reaction vessel 1, 2, ... n-1 , n), where n is an integer and each building block A n is unique.
- scaffold S is added to each reaction vessel to form an A n - S complex.
- scaffold S n can be added to each reaction vessel to from an A n -S n complex, where n is an integer of more than two, and each scaffold S n can be unique.
- building block B n is to each n reaction vessel containing the A n -S complex (i.e., building block B 1 ; B 2 , ... B n- i, B shadow is added to reaction vessel 1, 2, ... n-1, n containing the ApS, A 2 -S, ... A cleansing_i-S, A n -S complex), where each building block B n is unique.
- building block C n can be added to each n reaction vessel containing the B n -A n -S complex (i.e., building block C], C 2 , ... C n-) , C n is added to reaction vessel 1, 2, ... n-1, n containing the BpAj-S ... B n -A n -S complex), where each building block C combat is unique.
- the resulting library will have n 3 number of complexes having n 3 tags. In this manner, additional synthetic steps can be used to bind additional building blocks to further diversify the library.
- the resultant complexes can optionally be purified and subjected to a polymerization or ligation reaction using one or more primers.
- This general strategy can be expanded to include additional diversity nodes and building blocks (e.g., D, E, F, etc.).
- the first diversity node is reacted with building blocks and/or S and encoded by an oligonucleotide tag.
- additional building blocks are reacted with the resultant complex, and the subsequent diversity node is derivatized by additional building blocks, which is encoded by the primer used for the polymerization or ligation reaction
- oligonucleotide tags are added to the complex after or before each synthetic step.
- tag A n is bound to the functional group of the headpiece (i.e., tag Ai, A 2 , ... A n _i, A n is added to reaction vessel 1, 2, ... n-1 , n containing the headpiece).
- Each tag A n has a distinct sequence that correlates with each unique building block A n , and determining the sequence of tag A n provides the chemical structure of building block A n .
- additional tags are used to encode for additional building blocks or additional scaffolds.
- the last tag added to the complex can either include a primer sequence or provide a functional group to allow for binding (e.g., by ligation) of a primer sequence.
- the primer sequence can be used for amplifying and/or sequencing the oligonucleotides tags of the complex. Exemplary methods for amplifying and for sequencing include polymerase chain reaction (PCR), linear chain amplification (LCR), rolling circle amplification (RCA), or any other method known in the art to amplify or determine nucleic acid sequences.
- building block A n a DNA tag A n is ligated or primer extended to the headpiece.
- These reactions may be performed in a 1,000-well plate or 10 x 100 well plates. All reactions may be pooled, optionally purified, and split into a second set of plates.
- building block B shadow which also include 1,000 different variants.
- a DNA tag B n may be ligated to the A n -headpiece complex, and all reactions may be pooled.
- the resultant library includes 1 ,000 x 1 ,000 combinations of A n x B n (i.e., 1 ,000,000 compounds) tagged by 1 ,000,000 different combinations of tags.
- the same approach may be extended to add building blocks C n , D n , E n , etc.
- the generated library may then be used to identify compounds that bind to the target.
- the structure of the chemical entities that bind to the library can optionally be assessed by PCR and sequencing of the DNA tags to identify the compounds that were enriched.
- This method can be modified to avoid tagging after the addition of each building block or to avoid pooling (or mixing).
- the method can be modified by adding building block A n to n reaction vessels, where n is an integer of more than one, and adding the identical building block Bi to each reaction well.
- B] is identical for each chemical entity, and, therefore, an oligonucleotide tag encoding this building block is not needed.
- the complexes may be pooled or not pooled.
- the library is not pooled following the final step of building block addition, and the pools are screened individually to identify compound(s) that bind to a target.
- a BIND ® Reader from SRU Biosystems, Inc.
- a sensor surface in high throughput format (e.g., 384 well plates and 1 ,536 well plates).
- building block A rend may be encoded with DNA tag A réelle
- building block B dominance may be encoded by its position within the well plate.
- Candidate compounds can then be identified by using a binding assay (e.g., using a BIND ® Biosensor, also available by SRU Biosystems, Inc., or using an ELISA assay) and by analyzing the A n tags by sequencing, microarray analysis and/or restriction digest analysis. This analysis allows for the identification of combinations of building blocks A n and B shadow that produce the desired molecules.
- the method of amplifying can optionally include forming a water-in-oil emulsion to create a plurality of aqueous microreactors.
- the reaction conditions e.g., concentration of complex and size of microreactors
- concentration of complex and size of microreactors can be adjusted to provide, on average, a microreactor having at least one member of a library of compounds.
- Each microreactor can also contain the target, a single bead capable of binding to a complex or a portion of the complex (e.g., one or more tags) and/or binding the target, and an amplification reaction solution having one or more necessary reagents to perform nucleic acid amplification.
- the amplified copies of the tag will bind to the beads in the microreactors, and the coated beads can be identified by any useful method.
- a second library may be prepared in an iterative fashion. For example, one or two additional nodes of diversity can be added, and the second library is created and sampled, as described herein. This process can be repeated as many times as necessary to create molecules with desired molecular and pharmaceutical properties.
- any of the binding steps described herein can include any useful ligation technique or techniques.
- Exemplary ligation techniques include enzymatic ligation, such as use of one of more RNA ligases and/or DNA ligases, as described herein; and chemical ligation, such as use of chemically co-reactive pairs, as described herein.
- the scaffold S can be a single atom or a molecular scaffold.
- Exemplary single atom scaffolds include a carbon atom, a boron atom, a nitrogen atom, or a phosphorus atom, etc.
- Exemplary polyatomic scaffolds include a cycloalkyl group, a cycloalkenyl group, a heterocycloalkyl group, a
- heterocycloalkenyl group an aryl group, or a heteroaryl group.
- a heteroaryl scaffold include a triazine, such as 1,3,5-triazine, 1 ,2,3-triazine, or 1 ,2,4-triazine; a pyrimidine; a pyrazine; a pyridazine; a furan; a pyrrole; a pyrrolline; a pyrrolidine; an oxazole; a pyrazole; an isoxazole; a pyran; a pyridine; an indole; an indazole; or a purine.
- a triazine such as 1,3,5-triazine, 1 ,2,3-triazine, or 1 ,2,4-triazine
- a pyrimidine such as 1,3,5-triazine, 1 ,2,3-triazine, or 1 ,2,4-tria
- the scaffold S can be operatively linked to the tag by any useful method.
- S is a triazine that is linked directly to the headpiece.
- trichlorotriazine i.e., a chlorinated precursor of triazine having three chlorines
- S has three positions having chlorine that are available for substitution, where two positions are available diversity nodes and one position is attached to the headpiece.
- building block A n is added to a diversity node of the scaffold, and tag A n encoding for building block A n (“tag A n ”) is ligated to the headpiece, where these two steps can be performed in any order.
- S is a triazine that is operatively linked to the linker of a tag, where trichlorotriazine is reacted with a nucleophilic group (e.g., an amino group) of a PEG, aliphatic, or aromatic linker of a tag.
- a nucleophilic group e.g., an amino group
- S is a triazine that is operatively linked to building block A n .
- building block A n having two diversity nodes e.g., an electrophilic group and a nucleophilic group, such as an Fmoc-amino acid
- a linker e.g., the terminal group of a PEG, aliphatic, or aromatic linker, which is attached to a headpiece.
- trichlorotriazine is reacted with a nucleophilic group of building block A n .
- all three chlorine positions of S are used as diversity nodes for building blocks.
- additional building blocks and tags can be added, and additional scaffolds S n can be added.
- Exemplary building block A relies include, e.g., amino acids (e.g., alpha-, beta-, gamma-, delta-, and epsilon- amino acids, as well as derivatives of natural and unnatural amino acids), chemically co-reactive reactants (e.g., azide or alkyne chains) with an amine, or a thiol reactant, or combinations thereof.
- the choice of building block A n depends on, for example, the nature of the reactive group used in the linker, the nature of a scaffold moiety, and the solvent used for the chemical synthesis.
- Exemplary building block B n 's and C n 's include any useful structural unit of a chemical entity, such as optionally substituted aromatic groups (e.g., optionally substituted phenyl or benzyl), optionally substituted heterocyclyl groups (e.g., optionally substituted quinolinyl, isoquinolinyl, indolyl, isoindolyl, azaindolyl, benzimidazolyl, azabenzimidazolyl, benzisoxazolyl, pyridinyl, piperidyl, or pyrrolidinyl), optionally substituted alkyl groups (e.g., optionally substituted linear or branched Ci_ 6 alkyl groups or optionally substituted Ci_ 6 aminoalkyl groups), or optionally substituted carbocyclyl groups (e.g., optionally substituted cyclopropyl, cyclohexyl, or cyclohexenyl).
- aromatic groups e
- Particularly useful building block B features's and C n 's include those with one or more reactive groups, such as an optionally substituted group (e.g., any described herein) having one or optional substituents that are reactive groups or can be chemically modified to form reactive groups.
- exemplary reactive groups include one or more of amine (-NR 2 , where each R is, independently, H or an optionally substituted C
- a restriction site may be introduced, for example, in tag B n or C, volume where a complex can be identified by performing PCR and restriction digest with one of the corresponding restriction enzymes.
- the bifunctional linker between the headpiece and the chemical entity can be varied to provide an appropriate spacer and/or to increase the solubility of the headpiece in organic solvent.
- linkers are commercially available that can couple the headpiece with the small molecule library.
- the linker typically consists of linear or branched chains and may include a Ci. 10 alkyl, a heteroalkyl of 1 to 10 atoms, a C 2- io alkenyl, a C 2 _io alkynyl, C 5 .
- a poly alkyl glycol e.g., a poly ethylene glycol, such as -(CH 2 CH 2 0) n CH 2 CH 2 -, where n is an integer from 1 to 50
- the bifunctional linker may provide an appropriate spacer between the headpiece and a chemical entity of the library.
- the bifunctional linker includes three parts.
- Part 1 may be a reactive group, which forms a covalent bond with DNA, such as, e.g., a carboxylic acid, preferably activated by a N-hydroxy succinimide (NHS) ester to react with an amino group on the DNA (e.g., amino-modified dT), an amidite to modify the 5' or 3 '-terminus of a single-stranded headpiece (achieved by means of standard oligonucleotide chemistry), chemically co-reactive pairs (e.g., azido-alkyne cycloaddition in the presence of Cu(I) catalyst, or any described herein), or thiol reactive groups.
- DNA such as, e.g., a carboxylic acid, preferably activated by a N-hydroxy succinimide (NHS) ester to react with
- Part 2 may also be a reactive group, which forms a covalent bond with the chemical entity, either building block A n or a scaffold.
- a reactive group could be, e.g., an amine, a thiol, an azide, or an alkyne.
- Part 3 may be a chemically inert spacer of variable length, introduced between Part 1 and 2.
- Such a spacer can be a chain of ethylene glycol units (e.g., PEGs of different lengths), an alkane, an alkene, a polyene chain, or a peptide chain.
- the linker can contain branches or inserts with hydrophobic moieties (such as, e.g., benzene rings) to improve solubility of the headpiece in organic solvents, as well as fluorescent moieties (e.g. fluorescein or Cy-3) used for library detection purposes.
- Hydrophobic residues in the headpiece design may be varied with the linker design to facilitate library synthesis in organic solvents.
- the headpiece and linker combination is designed to have appropriate residues wherein the octanohwater coefficient (P oc t) is from, e.g., 1.0 to 2.5.
- Linkers can be empirically selected for a given small molecule library design, such that the library can be synthesized in organic solvent, for example, in 15%, 25%, 30%, 50%, 75%, 90%, 95%, 98%, 99%, or 100% organic solvent.
- the linker can be varied using model reactions prior to library synthesis to select the appropriate chain length that solubilizes the headpiece in an organic solvent.
- Exemplary linkers include those having increased alkyl chain length, increased poly ethylene glycol units, branched species with positive charges (to neutralize the negative phosphate charges on the headpiece), or increased amounts of hydrophobicity (for example, addition of benzene ring structures).
- linkers examples include amino-carboxylic linkers, such as those being peptides (e.g., Z-Gly-Gly-Gly-Osu (N-alpha-benzyloxycarbonyl-(Glycine) 3 -N-succinimidyl ester) or Z-Gly-Gly-Gly-Gly-Gly-Osu (N-alpha-benzyloxycarbonyl-(Glycine) 6 -N-succinimidyl ester, SEQ ID NO: 3)), PEG (e.g., Fmoc-aminoPEG2000-NHS or amino-PEG (12-24)-NHS), or alkane acid chains (e.g., Boc-s-aminocaproic acid-Osu); chemically co-reactive pair linkers, such as those chemically co- reactive pairs described herein in combination with a peptide moiety (e.g., azidohomoalanine-Gly
- linkers are known in the art, and those that can be used during library synthesis include, but are not limited to, 5'-0- dimethoxytrityl- ,2'-dideoxyribose-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 9-0- dimethoxytrityl-triethylene glycol, 1 -[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; 3-(4,4'- dimethoxytrityloxy)propyl- 1 -[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite; and 18-0- dimethoxytrityl hexaethyleneglycol,l-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite. Any of the linkers herein can be added
- Linkers may also be branched, where branched linkers are well known in the art and examples can consist of symmetric or asymmetric doublers or a symmetric trebler. See, for example, Newcome et al., Dendritic Molecules: Concepts, Synthesis, Perspectives, VCH Publishers (1996); Boussif et al., Proc. Natl. Acad. Sci. USA 92:7297-7301 (1995); and Jansen et al, Science 266: 1226 (1994).
- reaction conditions were explored to improve single-stranded ligation of tags to form an encoded library. These reaction conditions included using modified nucleotides within the tag (e.g., use of one or more nucleotides having a 2'-OMe group to form a MNA/DNA tag, where "MNA” refers to an oligonucleotide having at least one 2'-0-methyl nucleotide); using donor tags and acceptor tags having different lengths and varying the concentration of the tags; using different types of ligases, as well as combinations thereof (e.g., CircLigaseTM ssDNA ligase and/or T4 RNA ligase), and varying their concentration; purifying the complex by removing unreacted starting materials; using poly ethylene glycols (PEGs) having different molecular weights and varying their concentration; varying the temperature and duration for reaction, such as ligation; varying the concentration of various agents, including ATP, Co(NH 3 ) 6 Cl 3 , and
- FIG. 5C A scheme of the ligation reaction using ligase is shown in Figure 5A, and a typical denaturing polyacrylamide gel electrophoresis is shown in Figure 5B.
- the donor oligonucleotide was labeled at the 3 '-terminus and could be detected on a gel by scanning at 450 nm excitation on a StormTM 800 Phosphorlmager.
- the gel depicts an unligated donor (or starting material) and the ligated product.
- the adenylated donor can be resolved and distinguished from the starting material on this gel.
- Table 2 provides ligation efficiencies measured as a function of the composition of the oligonucleotide (i.e., oligonucleotides with all DNA nucleotides versus oligonucleotides with at least one 2'-0-methyl nucleotide, labeled "MNA") and the type of ligase (i.e., RNA ligase versus ssDNA ligase).
- MNA 2'-0-methyl nucleotide
- T4 RNA ligase included the following: 5 ⁇ each of donor and acceptor oligonucleotides (15-18 nucleotides (nts) long) in a buffer solution containing 50 niM Tris HC1, 10 mM MgCl 2 , 1 mM hexamine cobalt chloride, 1 mM ATP, 25% PEG4600, and 5 units of T4 RNA ligase (NEB- new units) at pH 7.5. The reactions were incubated at 37°C for 16 hours.
- CircLigaseTM included the following: 5 ⁇ each of donor and acceptor oligonucleotides (length 15 or 18 nts) incubated in a buffer containing 50 mM MOPS (pH 7.5), 10 mM KC1, 5 mM MgCl 2 , 1 mM DTT, 0.05 mM ATP, 2.5 mM MnCl 2 , and 25% (w/v) PEG 8000 with 20 units of CircLigaseTM (Epicentre) at 50°C for 16 hours. The reactions were resolved on 8M urea/15% PAAG, followed by densitometry using excitation at 450 nm. Table 2
- CircLigaseTM produced higher ligation yields than T4 RNA ligase (Table 2).
- donor and acceptor were DNA MNA hybrid oligonucleotides
- efficient ligation was achieved with T4 RNA ligase.
- Figure 5C shows high yield ligation achieved for T4 RNA ligase at high enzyme and oligonucleotide concentrations.
- the reaction conditions included following: 250 ⁇ each of donor and acceptor oligonucleotides in a buffer containing 50 mM Tris HCl, 10 mM MgCl 2 , 1 mM hexamine cobalt chloride, 2.5 mM ATP, 30% (w/v) PEG4600, pH 7.5, different amounts of T4 RNA ligase at 40 units/ uL (NEB- new units), and 0.1 unit of yeast inorganic pyrophosphatase. The reactions were incubated at
- enzymatic ligation can be optimized by including one or more modified 2 '-nucleotides and/or by using an RNA or DNA ligase. Further details for several other tested conditions, such as PEG or tag length, that can contribute to ligation efficiency are discussed below.
- oligonucleotide tags were DNA sequences with one or two terminal 2'O-methyl (2'-OMe) RNA bases (e.g., 2'-OMe-U (mU) or 2'-OMe- G (mG)).
- acceptor and donor tags of various lengths were constructed.
- a 15mer donor having the sequence 5'-P-mGTG CAG GTA GAG TGC-6-FAM-3' (SEQ ED NO: 12) was used and paired with 10, 12, 14, 16, and 18mer DNA acceptor oligonucleotides.
- the tags included one or more 2'-OMe-bases (designated as being MNA/DNA tags). Table 3 provides the sequence for the three donor tags (15mer, 8mer, and 5mer) and the three acceptor tags (15mer, 8mer, and 5mer).
- T4 RNA ligase may be preferred for tag ligation.
- ligation can be further optimized by using CircLigaseTM or a combination of T4 RNA ligase and CircLigaseTM.
- tags included 15mer donor and 15mer acceptor tags, as provided above in Table 3.
- the chemical entity was bound to the 3 '-terminus of the library, where the chemical entity was fluorescein in this example to aid in visualization.
- Figure 9 (right), successive tags were ligated to the 5' -OH group of the complex after phosphorylation by T4 PNK.
- the methods described herein can further include chemically co-reactive pair ligation techniques, as well as enzyme ligation techniques.
- chemical ligation an exemplary chemically co-reactive pair (i.e., an alkyne and an azido pair in a cycloaddition reaction) in two variants: a short chemically co-reactive pair and a long chemically co-reactive pair, was used.
- a short chemically co-reactive pair (Figure 10A) was used.
- the pair included (i) an oligonucleotide having the sequence 5'-GCG TGA ACA TGC ATC TCC CGT ATG CGT ACA GTC CAT T/propargylG/-3' ("5end3propargyl," SEQ ID NO: 18) and (ii) an oligonucleotide having the sequence 5 ' -/azidoT/ATA GCG CGA TAT ACA C AC TGG CGA GCT TGC GTA CTG-3 '
- the 5'-azido oligonucleotide (3end5azido) was prepared by converting the iodo group in the corresponding 5'-iodo oligonucleotide into an azido group.
- a long chemically co-reactive pair (Figure 10B) was used.
- the pair included (i) an oligonucleotide having the sequence 5'-GCG TGA ACA TGC ATC TCC CGT ATG CGT ACA GTC CAT TG/spacer7-azide/-3' ("5end3azide," SEQ ID NO: 20) and (ii) an oligonucleotide having the sequence 5'-/hexynyl/TA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG-3'
- 3end5hexynyl SEQ ID NO: 21.
- This pair of oligonucleotides was prepared by Integrated DNA Technologies, Inc. (IDT DNA, San Diego, CA, and Coralville, IA).
- the 5end3azide oligonucleotide was prepared by reacting an azidobutyrate N-hydroxysuccinimide ester with a 3'-amino-modifier C7 (2- dimethoxytrityl oxymethyl-6-fluorenylmethoxycarbonylamino-hexane-l -succinoyl-long chain alkylamino), which was introduced during oligonucleotide column synthesis.
- This pair was designed to produce a 24 atom long spacer between the oligonucleotides (counting from the C3' -position of the 5end3azide oligonucleotide to the C5'-position of the 3end5hexynyl oligonucleotide).
- the primers and templates included the following: a reverse transcription primer having the sequence of 5'-/Cy5/ CAG TAC GCA AGC TCG-3' ("Cy5s_primerl5,” SEQ ID NO: 22); a control template having the sequence of 5'-GCG TGA ACA TGC ATC TCC CGT ATG CGT ACA GTC CAT TGT ATA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG-3' ("templ75,” SEQ ID NO: 23); a 5'-PCR primer having the sequence of 5'-GCG TGA ACA TGC ATC TCC-3' (SEQ ID NO: 24); and a 3'-PCR primer having the sequence of 5'-CAG TAC GCA AGC TCG CC-3' (SEQ ID NO: 25), where these sequences were obtained from IDT DNA.
- a Cy5 -labeled DNA primer was used for the experiments to enable separate detection of the reverse transcription products by
- LC-MS Liquid chromatography-mass spectrometry
- Reverse transcription reactions were performed using ThermoScriptTM RT (Invitrogen Corp.), according to the manufacturer's protocol, at 50°C for 1-2 hours. The results were analyzed by LC-MS and by PCR. PCR was performed using Platinum® SuperMix and resolved on 4% agarose E-Gels (both from Invitrogen Corp.). Eleven and eighteen cycles of PCR were performed with or without a preceding RT reaction. The 75mer template was not reverse transcribed and used directly for the PCR
- reaction yields were high, close to quantitative, as analyzed by LC-MS. Accordingly, chemical ligation provides a high yield technique to bind or operatively associate a headpiece to one or more building block tags.
- the resultant complex should be capable of undergoing PCR or RT-PCR for further sequencing applications. While PCR and RT-PCR may not be an issue with enzymatically ligated tags, such as described above, unnatural chemical linkers may be difficult to process by RNA or DNA polymerases.
- the data provided in Figures. 1 lB-1 IE suggest that oligonucleotides having a spacer of particular lengths can be transcribed and/or reverse transcribed.
- RT-PCR was performed with the templates described above and revealed that only the short linker yielded reverse transcription product, albeit at 5-10 lower efficiency (Figure 1 IE). Efficiency of the RT was estimated to be about 2-fold lower than the template (templ75). For example, the PCR product of the short ligated template around 2-fold lower after RT and around 5-10 times lower without RT, as compared to the PCR product of the all-DNA template 75 (templ75). Accordingly, these data provide support for the use of chemical ligation to produce a complex that can be reverse transcribed and/or transcribed, and chemically ligated headpieces and/or tags can be used in any of the binding steps described herein to produce encoded libraries.
- oligonucleotides having other modifications were determined.
- analogs of the natural phosphodiester linkage e.g., a phosphorothioate analog
- oligonucleotides were synthesized by TriLink BioTechnologies, Inc. (San Diego, CA): (i) 5VCy5/ CGA TAT ACA CAC TGG CGA GCT/thiophosphate/-3' ("CCy5,” SEQ ID NO: 26), (ii) 5'-/IododT/ GC GTA CTG AGC/6-FAM/-3 ' ("CFL,” SEQ ID NO: 27), as shown in Figure 12A, and
- a splint oligonucleotide having the sequence of CAG TAC GCA AGC TCG CC (“spl,” SEQ ID NO: 28).
- Ligation reactions were performed with 100 uM of each reactant oligonucleotide in a buffer containing 50mM Tris HC1 (pH 7.0), 100 niM NaCl, and 10 n M MgCl 2 ("ligation buffer") at room temperature.
- the ligation reactions were supplemented by either of the following: 100 uM of the splint oligonucleotide, 10 niM Co(NH 3 ) 6 Cl 3 , 40% (w/v) of PEG4000, or 80% (w/v) of PEG300.
- Ligation products were analyzed by LC-MS using detection at 260 nm, 495 nm, and 650 nm, as well as by an 8M urea/ 15% polyacrylamide gel (PAAG) that was further scanned at 450 and 635 nm excitation on a StormTM 800 Phosphorlmager.
- PAAG polyacrylamide gel
- FIG. 12D shows LC-MS analysis of the ligation of CFL and CCy5 in the absence (top) and presence (bottom) of a splint (positive control), where ligation reactions were incubated for seven days.
- CCy5 (7329 Da) were detected ( Figure 12D, top).
- a characteristic peak was observed in 495 nm channel with a retention time of 2.98 min, which corresponds to the ligated product (11542 Da) ( Figure 12D, bottom). This peak overlapped with that for the CCy5 oligonucleotide observed at the 650 nm channel and, thus, was indistinguishable from CCy5 at 650 nm.
- Figure 12E shows the LC-MS analysis of CFL and CCy5 in the absence of a splint, where ligation reactions were incubated for eight days at 400 ⁇ of each oligonucleotide. No ligation product was detected.
- Peak 1 (at 495 nm) contained CFL starting material (4339 Da), as well as traces of the loss of iodine product (4211 Da) and an unknown degradation product (4271 Da, possibly ethyl mercaptane displacement).
- Peak 2 at 650 nm
- Peak 2 contained CCy5 starting material (7329 Da) and oxidized CCy5 oligonucleotide (7317 Da).
- Peak 3 at 650 nm) contained dimerized CCy5 (14663 Da).
- oligonucleotide with piperidine where this reaction was intended to displace the terminal iodine present in CFL.
- One reaction condition included oligonucleotides at 100 ⁇ , piperidine at 40 mM (400 equivalents) in 100 mM borate buffer, pH 9.5, for 20 hrs at room temperature (data shown in left panel of Figure 12F); and another reaction condition included oligonucleotides at 400 ⁇ , piperidine at 2 M (4,000 equivalents) in 200 mM borate buffer, pH 9.5, for 2 hrs at 65°C (data shown in right panel of Figure 12F).
- oligonucleotides at 50 ⁇ performed in the presence of 400 equivalents of piperidine in 100 mM borate buffer, pH 9.5, for 20 hrs at room temperature.
- the characteristic peak detected in the LC trace contained predominantly the product of ligation at 11541.3 Da (calc'd 11540 Da). Based on these results, it can be concluded that that piperidine does not impair enzymatic ligation and that the presence of other amines (e.g., as part of chemical library synthesis) will likely not interfere with this ligation strategy.
- Shuffling can result in the inclusion or excision of a nucleotide, where the final product or complex includes or excludes a nucleotide compared to the expected ligated sequence (i.e., a sequence having the complete sequence for both the acceptor and donor
- shuffling can be minimized by including a modified phosphate group.
- the modified phosphate group is a phosphorothioate linkage between the terminal nucleotide at the 3 '-terminus of an acceptor oligonucleotide and the nucleotide adjacent to the terminal nucleotide. By using such a phosphorothioate linkage, shuffling was greatly reduced.
- one or more modified phosphate groups could be included in any oligonucleotide sequence described herein (e.g., between the terminal nucleotide at the 3'-terminus of a headpiece, a complex, a building block tag, or any tag described herein, and the nucleotide adjacent to the terminal nucleotide) to minimize shuffling during single-stranded ligation.
- modified phosphate groups e.g., a phosphorothioate or a 5'-N-phosphoramidite linkage
- a single stranded headpiece (ssHP, 3636 Da) was phosphorylated at the 5 '-terminus and modified with a hexylamine linker at the 3 '-terminus to provide the sequence of 5'-P- mCGAGTC ACGTC/Aminohex/-3 ' (SEQ ED NO: 29).
- the headpiece was ligated to a tag (tag 15, XTAGSS000015, 2469 Da) having the sequence of 5'-mCAGTGTCniA-3' (SEQ ID NO: 30), where mC and niA indicate 2'-0 methyl nucleotides.
- Figure 13B illustrates a possible scheme for nucleotide reshuffling during T4 RNA ligase reaction between a headpiece and a tag, where one of skill in the art would understand that this reaction could occur between any donor and acceptor oligonucleotides (e.g., between two tags, where one tag is the donor oligonucleotide and the other tag is the acceptor oligonucleotide).
- T4Rnll T4 RNA ligase
- Figure 13B-1 reaction on left
- Figure 13B-2 reaction on right
- aberrant ligation products include those having the removal or addition of a terminal nucleotide ("Product -1 nt" and "Product + 1 nt,” respectively, in Figure 13B-2).
- This HP-1 nt headpiece is re-adenylated by T4 RNA ligase (to provide "Adenylated HP-1 nt" in Figure 13B-2) and ligated to the tag, resulting in a ligation product minus one nucleotide ("Product- 1 nt").
- the adenylated nucleotide (1 nt) likely serves as a substrate for ligation to the tag, thereby producing an oligonucleotide having one nucleotide longer than the acceptor ("Tag+1 nt").
- This Tag+1 nt oligonucleotide likely serves as an acceptor for the unaltered headpiece, where this reaction provides a ligation product having an additional nucleotide ("Product+1 nt”).
- LC-MS analyses of "Product”, “Product-1 nt”, and “Product+1 nt” were performed ( Figure 13B-3).
- an aberrant tag and an aberrant headpiece i.e., Tag+1 nt and HP-1 nt, respectively
- the resultant ligation product is indistinguishable from the expected product.
- a headpiece having the sequence of 5'P-mC*GAGTCACGTC/Aminohex/-3' (SEQ ID NO: 31) was prepared.
- Headpiece HP -PS has the same sequence as ssHP but contains one modification, namely the first phosphodiester linkage between 5 '-terminal nucleotide mC and the following G was synthesized as a phosphorothioate linkage (one non-bridging phosphate oxygen was substituted by a sulfur).
- LC-MS analysis of the HP-PS ligation to tag 15 revealed that shuffling was almost completely inhibited (Figure 13C). Traces of +/- 320 peaks likely correspond to the oxidative conversion of the phosphorothioate linkage into native phosphodiester linkages or incomplete sulfurization.
- SEC size exclusion chromatography
- the ratio of protein target to library molecule was 2:1, so approximately 50% of the library molecules should associate with the protein in the early eluting fraction, as observed in Figure 14.
- Libraries with larger, double-stranded oligonucleotide coding regions cannot be selected using this method since the unbound library members co-migrate with the bound library members on SEC.
- small molecule libraries attached to encoding single-stranded oligonucleotides in the 20-50mer length range enable the use of a powerful separation technique that has the potential to significantly increase the signal-to-noise ratio required for the effective selection of small molecule binders to one or more targets, e.g., novel protein targets that are optionally untagged and/or wild-type protein.
- targets e.g., novel protein targets that are optionally untagged and/or wild-type protein.
- these approaches allow for identifying target-binding chemical entities in encoded combinatorially-generated libraries without the need for tagging or immobilizing the target (e.g., a protein target).
- Encoding DNA tags can be ligated enzymatically or chemically. A general approach to chemical
- DNA tag ligation is illustrated in Figure 15 A.
- Each tag bears co-complementary reactive groups on its 5 ' and 3' ends.
- protection of one or both reactive groups e.g., in case of TIPS -protected 3' alkynes
- Figure 15B splint-dependent ligation chemistry
- unligated tags can be removed or capped after each library cycle to prevent mistagging or polymerization of the deprotected tag. This step may be optional for (ii), but may still be included.
- Primer extension reactions using polymerase enzymes that are capable of reading through chemically ligated junctions, can also be performed to demonstrate that ligated tags are readable and therefore the encoded information is recoverable by post-selection amplification and sequencing (Figure 15C).
- FIG. 16A A library tagging strategy that implements ligation of the tags using "click-chemistry" (Cu(I) catalyzed azide/alkyne cycloaddition) is shown in Figure 16A.
- the implementation of this strategy relies on the ability of precise successive ligation of the tags, avoiding mistagging, and tag polymerizations, as well as the ability to copy the chemically ligated DNA into amplifiable natural DNA (cDNA) for post- selection amplification and sequencing (Figure 16C).
- the TIPS protecting group can be specifically removed by treatment with tetrabutylammonium fluoride (TBAF) in DMF at 60°C for 1 -4 hours.
- TBAF tetrabutylammonium fluoride
- the ligation during library synthesis includes a 5'-azido/3'-TIPS-propargyl nucleotide (Tag A) reacting with the 3'-propargyl of the headpiece through a click reaction.
- the previous cycle is treated with TBAF to remove TIPS and generate the reactive alkyne which in turn reacts with the next cycle tag.
- the procedure is repeated for as many cycles as it is necessary to produce 2, 3 or 4 or more successively installed encoding tags ( Figure 16 A).
- Oligos The following oligos were synthesized by Trilink Biotechnologies, San Diego CA: ss- HP-alkyne: 5'- NH 2 -TCG AAT GAC TCC GAT AT (3'-Propargyl G)-3'(SEQ ID NO: 32); ss-azido-TP: 5'-azido dT ATA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG -3'(SEQ ID NO: 33); and B-azido: 5' azido dT ACA CAC TGG CGA GCT TGC GTA CTG -3' (SEQ ID NO: 34).
- ClickTag-TIPS 5'-azdido dT AT GCG TAC AGT CC (propargyl U-TIPS)-3' (SEQ ID NO: 35) and 5'Dimethoxytrityl 2'-succinyl 3'-0-(triisopropyl silyl) Propargyl uridine cpg were synthesized by Prime Organics, Woburn MA.
- FAM-click- primer (5'-6-FAM) CAG TAC GCA AGC TCG CC -3' (SEQ ID NO: 36) and Cy5 -click-primer: (5'- Cy5) CAG TAC GCA AGC TCG CC -3' (SEQ LD NO: 37).
- DNA55-control /5'Biotin-TEG//ispC3//ispC3/-TCGAATGACTCCGATATGT ATA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG -3' (SEQ LD NO: 38).
- rDNA55-control /5Bio-TEG//ispC3//ispC3/-TCGAATGACTCCGATAT(riboG)T ATA GCG CGA TAT ACA CAC TGG CGA GCT TGC GTA CTG -3' (SEQ LD NO: 39)
- templates In the following examples, the phrase “chemically ligated tags”, or control sequences related to them, are referred to as “templates” because the subsequent step ("reading") utilizes them as templates for template-dependent polymerization.
- Single click templates Y55 and Y185 were synthesized by the reaction of ss-HP-alkyne with ss-azido-TP and B-azido, respectively.
- Double and triple click templates (YDC and YTC) were synthesized by click ligation of ss-HP-alkyne with ClickTag-TIPS, followed by deprotection of TLPS using TBAF (tetrabutylammonium fluoride) in DMF at 60°C for an hour, followed by click ligation with ss-azido TP.
- TBAF tetrabutylammonium fluoride
- the templates were reacted with biotin-(EG) 4 -NHS and desalted (Figure 17A).
- the final products were purified by RP HPLC and/or on a 15-20% polyacryl amide gel/ 8M urea and analyzed by LC-MS.
- Enzymes The following DNA polymerases with their reaction buffers were purchased from New England Biolabs: Klenow fragment of E. coli DNA polymerase I, Klenow fragment (exo-), E. coli DNA polymerase I, TherminatorTM, 9°NTM, Superscript IIITM .
- Streptavidin magnetic Dynabeads® M280 were purchased from Invitrogen.
- Template-dependent polymerization assessment Each template (5 ⁇ ) was incubated with 1 equivalent of either Cy5 or FAM Click-primer in 40 to 50 ⁇ of the corresponding lx reaction buffer and each enzyme, using reaction conditions according to the manufacturer's guidelines for 1 hour. Certain reactions (such as SSII or SSIII transcriptions) were additionally supplemented with 1 mM MnCl 2 . The product of the reaction was loaded on 125 ⁇ of pre-washed SA beads for 30 minutes with shaking. The beads were then collected, and the flowthrough was discarded. Beads were washed with 1 mL of Tris- buffered saline (pH 7.0) and eluted with 35 ⁇ , of 100 mM NaOH. The eluate was immediately neutralized by adding 10 ⁇ of 1 M Tris HC1, pH 7.0. The products were analyzed using LC-MS.
- the single click templates Y55 and Y185 were synthesized from oligonucleotides that bear only one click chemistry functionality (alkyne or azide). The efficiency of the click reaction (chemical ligation) was over 90% in an overnight reaction using Cu(I) catalyst generated in situ.
- Templates YDC and YTC serve to demonstrate successive chemical ligations. Both YDC and YTC use individual tags which simultaneously contain both azido and TIPS- protected alkyne functionalities. Template YTC demonstrates three successive cycles of tagging as may be used to encode three steps of chemical library generation.
- Template-dependent polymerization using "single-click" template Y55 A large set of polymerases was tested to read through a triazole click linkage (Figure 18A). Initial experiments were performed using Cy5 -click-primer. In later experiments FAM-click-primer was used. The fluorophore had no effect on the copying of the template, i.e., the results were equivalent using either primer. As a control template DNA55 -control and rDNA55 -control were used (to test the effect of a single ribonucleotide in the template, since propargyl-G used for a click ligation is a ribonucleotide derivative).
- Superscript IIITM reverse transcriptase produced about 50% yield of cDNA when the buffer was supplemented with 1 mM MnCl 2 .
- manganese caused the mis-incorporation of nucleotides which was observed by MS, i.e., polymerization fidelity was reduced.
- Template-dependent polymerization using " ingle-click" template Y185 features the same primer binding site as all templates used in this example, except, due to a different tailpiece B- azido, the distance between the last nucleotide of the primer binding site to the click linkage is 8 nucleotides, as compared to 20 nucleotides in Y55 and all other templates.
- the template was used to test whether transcription of a click linkage was still possible when the enzyme was in initiation-early elongation conformation. Klenow was capable of copying the Yl 85 template with similar efficiency to Y55, opening the possibility of reducing the length of the click-ligated encoding tags (Figure 18C).
- Template-dependent polymerization using double and triple click-ligated templates YDC and YTC After establishing that the Klenow fragment was the most efficient enzyme to read through the click ligation linkages under the assay condition employed, cDNA using YDC and YTC templates ( Figures 20A-20C) were also generated. Primer extension reactions with both YDC and YTC templates produced full length products. Other observed products, which composed around 10-15% of total reaction output, corresponded to partially extended primer, stalled at each click junction, such as e.g., 11880 Da and 16236 Da. The yields were measured by LC-MS analysis in the presence of the internal standard and were about 80-90% per junction (i.e., around 85% for 1 click, 55% for 2-click and 50% for 3-click templates, see Figure 21).
- Cycle A To each well in the split was added single-stranded DNA headpiece (1 eq., 1 mM solution in 500 mM pH 9.5 borate buffer), one cycle A protected tag (1.5 eq.), and splint (1.2 eq.). The chemical ligation was incubated at room temperature overnight. To each well (in the split) was then added one Fmoc amino acid (100 eq.), followed by 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4- methylmorpholinium chloride (100 eq.). The chemical reaction was incubated at room temperature overnight. Upon completion, all wells were pooled and the products precipitated using ethanol.
- cycle A pool was purified using LC and lyophilized to dryness, and then dissolved in water to give a 1 mM final concentration and piperidine (10% v/v) was added to perform the deprotection of cycle A tag (60°C, 2h). The deprotected product was precipitated again using ethanol.
- Cycle B The deprotected cycle A pool was dissolved in 500 mM, pH 9.5, borate buffer to give a lmM concentration and then split into separate reaction wells (1 eq. of cycle A product in each well). To each well was added one cycle B protected tag (1.5 eq.), and splint (1.2 eq.). The chemical ligation was incubated at room temperature overnight. To each well (in the split) was added a mixture of one formyl acid (100 eq.), diisopropyl carbodiimide (100 eq.) and 1 -hydroxy-7-aza-benzotriazole (100 eq.). The chemical reaction was incubated at room temperature overnight.
- cycle B The cycle B pool was purified using LC and lyophilized to dryness, and then dissolved in water to give a 1 mM final concentration and piperidine (10% v/v) was added to perform the deprotection of cycle B tag (60°C, 2h). The deprotected product was precipitated again using ethanol.
- Cycle C The deprotected cycle B pool was dissolved in 500 mM pH 5.5 phosphate buffer to give a 1 mM concentration and then split into separate reaction wells (1 eq. of cycle B product in each well). To each well was added one cycle C tag (1.5 eq.) and splint (1.2 eq.).
- the chemical ligation was incubated at room temperature overnight. To each well (in the split) was added an amine (80 eq.) and sodium cyanoborohydride (80 eq.). The chemical reaction was incubated at 60°C for 16h. Upon completion, all wells were pooled and the products precipitated using ethanol. The cycle C pool was purified using LC and lyophilized to dryness.
- Orthogonal chemical ligation strategy utilizing 5 '-Azido/3 '-Alkynyl and 5 '-Iodo/3 '- Phosphorothioate ligation for successive steps:
- An example of the use of two orthogonal chemistries tag ligation is the combination of 5'-azido/3'-alkynyl and 5 '-iodo/3 '-phosphorothioate ligations.
- Figure 23 shows an exemplary schematic of the synthesis of a 3-cycle orthogonal chemical ligation tagging strategy using these successive ligation chemistries.
- Figures 25A-25B show an example of the use of 3'- phosphorothioate/5'-azido and 3'-propargyl/5'-iodo tags to chemically ligate a succession of orthogonal encoding DNA tags that encode a chemical library covalently installed upon the '-terminus.
- Cycle A To each well in the split was added single stranded DNA headpiece (1 eq., 1 mM solution in 500 mM pH 9.5 borate buffer), one cycle A tag (1.5 eq.), and splint (1.2 eq.). The chemical ligation was incubated at room temperature overnight. To each well (in the split) was then added one Fmoc amino acid (100 eq.), followed by 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4-methylmo ⁇ holinium chloride (100 eq.). The chemical reaction was incubated at room temperature overnight. Upon completion, all wells were pooled and the products precipitated using ethanol.
- cycle A pool was purified using LC and lyophilized to dryness. Fmoc deprotection was performed on cycle A pool by treating the pool (ImM in water) with piperidine (10% v/v) for 2h at room temperature. The deprotected product was precipitated again using ethanol.
- Cycle B The purified cycle A pool was dissolved in 500 mM, pH 7.0 phosphate buffer to give a 1 mM concentration and then split into separate reaction wells (1 eq. of cycle A product in each well). To each well was added one cycle B protected tag (1.2 eq.), copper (II) acetate (2 eq.), sodium ascorbate (4 eq.), and tris-(benzyltriazolylmethyl)amine (1 eq.). The chemical ligation was incubated at room temperature overnight. Upon completion, the products were precipitated (in the split) using ethanol and then diluted to a 1 mM concentration using 500 mM, pH 9.5 borate buffer.
- Cycle C The purified cycle B pool was dissolved in 500 mM, pH 5.5 phosphate buffer to give a 1 mM concentration and then split into separate reaction wells (1 eq. of cycle B product in each well). To each well was added one cycle C tag (1.5 eq.) and splint (1.2 eq.). The chemical ligation was incubated at room temperature overnight. To each well (in the split) was added an amine (80 eq.) and sodium cyanoborohydride (80 eq.). The chemical reaction was incubated at 60°C for 16h. Upon completion, all wells were pooled and the products precipitated using ethanol. The cycle C pool was purified using LC and lyophilized to dryness.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Structural Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/343,306 US10865409B2 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging DNA-encoded libraries |
KR1020147007749A KR102124613B1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
BR112014005205A BR112014005205A2 (en) | 2011-09-07 | 2012-09-07 | methods for tagging dna encoded libraries |
EP20205449.0A EP3828271A1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
CA2848023A CA2848023C (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
AU2012304387A AU2012304387B2 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging DNA-encoded libraries |
AP2014007483A AP2014007483A0 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging DNA-encoded libraries |
SG11201400374TA SG11201400374TA (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
MX2014002854A MX360438B (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries. |
IN2574CHN2014 IN2014CN02574A (en) | 2011-09-07 | 2012-09-07 | |
ES12830083.7T ES2675111T3 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging libraries with DNA coding |
CN201280053930.2A CN103998658B (en) | 2011-09-07 | 2012-09-07 | Method for marking DNA-coding libraries |
EA201490534A EA032438B1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
DK12830083.7T DK2748357T3 (en) | 2011-09-07 | 2012-09-07 | Methods for labeling DNA-encoded libraries |
KR1020207017041A KR102242879B1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
JP2014529907A JP6674738B2 (en) | 2011-09-07 | 2012-09-07 | Method for tagging a DNA code library |
EP12830083.7A EP2748357B1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
EP18158771.8A EP3351631B1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
NZ621592A NZ621592B2 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
IL231191A IL231191B (en) | 2011-09-07 | 2014-02-27 | Methods for tagging dna-encoded libraries |
AU2017201146A AU2017201146B2 (en) | 2011-09-07 | 2017-02-20 | Methods for tagging DNA-encoded libraries |
AU2019200965A AU2019200965B2 (en) | 2011-09-07 | 2019-02-12 | Methods for tagging DNA-encoded libraries |
US16/869,271 US20210002630A1 (en) | 2011-09-07 | 2020-05-07 | Methods for tagging dna-encoded libraries |
IL279796A IL279796A (en) | 2011-09-07 | 2020-12-27 | Methods for tagging dna-encoded libraries |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531820P | 2011-09-07 | 2011-09-07 | |
US61/531,820 | 2011-09-07 | ||
US201161536929P | 2011-09-20 | 2011-09-20 | |
US61/536,929 | 2011-09-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/343,306 A-371-Of-International US10865409B2 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging DNA-encoded libraries |
US16/869,271 Continuation US20210002630A1 (en) | 2011-09-07 | 2020-05-07 | Methods for tagging dna-encoded libraries |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013036810A1 true WO2013036810A1 (en) | 2013-03-14 |
Family
ID=47832597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/054228 WO2013036810A1 (en) | 2011-09-07 | 2012-09-07 | Methods for tagging dna-encoded libraries |
Country Status (18)
Country | Link |
---|---|
US (2) | US10865409B2 (en) |
EP (3) | EP3351631B1 (en) |
JP (3) | JP6674738B2 (en) |
KR (2) | KR102242879B1 (en) |
CN (1) | CN103998658B (en) |
AP (1) | AP2014007483A0 (en) |
AU (3) | AU2012304387B2 (en) |
BR (1) | BR112014005205A2 (en) |
CA (2) | CA3077662A1 (en) |
DK (2) | DK2748357T3 (en) |
EA (1) | EA032438B1 (en) |
ES (2) | ES2852073T3 (en) |
HK (1) | HK1258815A1 (en) |
IL (2) | IL231191B (en) |
IN (1) | IN2014CN02574A (en) |
MX (2) | MX360438B (en) |
SG (2) | SG11201400374TA (en) |
WO (1) | WO2013036810A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015091207A1 (en) * | 2013-12-20 | 2015-06-25 | Philochem Ag | Production of encoded chemical libraries |
WO2015135856A1 (en) * | 2014-03-14 | 2015-09-17 | Philochem Ag | Purification of dna-conjugate products |
EP2872680A4 (en) * | 2012-07-13 | 2016-01-27 | Chem Inc X | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
EP2186897B1 (en) * | 2002-03-15 | 2016-02-17 | Nuevolution A/S | An improved method for synthesising templated molecules |
US9359601B2 (en) | 2009-02-13 | 2016-06-07 | X-Chem, Inc. | Methods of creating and screening DNA-encoded libraries |
EP2748357B1 (en) | 2011-09-07 | 2018-04-04 | X-Chem, Inc. | Methods for tagging dna-encoded libraries |
US10072283B2 (en) | 2010-09-24 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
WO2019140353A1 (en) * | 2018-01-12 | 2019-07-18 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
WO2019157692A1 (en) * | 2018-02-14 | 2019-08-22 | 深圳劲宇生物科技有限公司 | Dna-encoded molecular library and target restriction-free compound screening method |
WO2019157693A1 (en) * | 2018-02-14 | 2019-08-22 | 深圳劲宇生物科技有限公司 | Dna-coded molecular library and widely-applicable compound screening method |
AU2015374309B2 (en) * | 2014-12-30 | 2020-06-11 | X-Chem, Inc. | Methods for tagging DNA-encoded libraries |
US11407993B2 (en) * | 2017-02-14 | 2022-08-09 | Technische Universitaet Dortmund | Method for the synthesis of DNA conjugates by micellar catalysis |
EP3924509A4 (en) * | 2019-05-09 | 2022-12-28 | Pacific Biosciences Of California, Inc. | Compositions and methods for improved cdna synthesis |
EP3515880B1 (en) | 2017-03-17 | 2023-05-10 | Hitgen Inc. | Methods and compositions for synthesis of encoded libraries |
US11965211B2 (en) | 2008-09-05 | 2024-04-23 | Aqtual, Inc. | Methods for sequencing samples |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016505826A (en) * | 2012-12-10 | 2016-02-25 | フレッド ハッチンソン キャンサー リサーチ センター | Screening method |
CN103882532B (en) * | 2012-12-20 | 2015-10-21 | 成都先导药物开发有限公司 | A kind of synthesis of lead compound and screening method and test kit |
CA2891966A1 (en) * | 2012-12-20 | 2014-06-26 | Sirna Therapeutics, Inc. | Post-synthetic orthogonal amidation plus metal catalyzed azide-alkyne cycloaddition click chemistry on sirna |
CN104894651B (en) * | 2015-06-29 | 2017-04-12 | 天津诺禾医学检验所有限公司 | Building method of high-throughput sequencing library of trace starter DNA (deoxyribonucleic acid) and high-throughput sequencing library built by building method |
EP3472376A4 (en) * | 2016-06-16 | 2019-12-18 | Richard Edward Watts | Oligonucleotide directed and recorded combinatorial synthesis of encoded probe molecules |
CN107130300A (en) * | 2016-10-08 | 2017-09-05 | 深圳劲宇生物科技有限公司 | The synthetic method and DNA profiling of a kind of DNA encoding library of molecules |
US11359227B2 (en) * | 2016-12-09 | 2022-06-14 | University Of Southern California | Genome-wide mapping of DNA-DNA proximities in the nucleus |
EP3619340A4 (en) * | 2017-05-02 | 2021-01-20 | Haystack Sciences Corporation | Molecules for verifying oligonucleotide directed combinatorial synthesis and methods of making and using the same |
CA3068446A1 (en) * | 2017-06-30 | 2019-01-02 | The Regents Of The University Of California | Methods and systems for evaluating dna methylation in cell-free dna |
CN111295444A (en) * | 2017-09-25 | 2020-06-16 | 哈斯达克科学公司 | Polynomial coding for oligonucleotide-directed combinatorial chemistry |
CN108070009B (en) * | 2017-12-12 | 2021-04-13 | 上海药明康德新药开发有限公司 | Method for preparing DNA coding compound library and initial fragment compound and prepared DNA coding compound |
WO2019149198A1 (en) * | 2018-01-31 | 2019-08-08 | 成都先导药物开发股份有限公司 | Dna-encoded compound library and compound screening method |
CA3095292A1 (en) | 2018-04-02 | 2019-10-10 | Progenity, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
WO2020001560A1 (en) * | 2018-06-29 | 2020-01-02 | 成都先导药物开发股份有限公司 | Reaction monitoring method in synthetic dna coding compound |
CN109468310B (en) * | 2018-10-25 | 2020-12-01 | 深圳劲宇生物科技有限公司 | Method for synthesizing DNA coding fragment molecule library and method for screening connecting group |
EP3899521A4 (en) | 2018-12-20 | 2022-08-24 | Sergey N. Krylov | Binder selection using capillary electrophoresis |
WO2020171092A1 (en) * | 2019-02-18 | 2020-08-27 | 味の素株式会社 | Method for producing modified oligonucleotide including complementary sequence |
WO2020206170A1 (en) | 2019-04-02 | 2020-10-08 | Progenity, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
CN114144522A (en) * | 2019-07-25 | 2022-03-04 | X-化学有限公司 | Methods for labeling and encoding pre-existing compound libraries |
WO2023077001A1 (en) * | 2021-10-27 | 2023-05-04 | Juan Pablo Maianti | Dna-encoded and affinity-tagged masked-warhead compounds and use thereof in assembling libraries of small molecules enabled for late-stage purification and multiplexed screening of covalent ligands |
WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867290B2 (en) * | 1999-04-30 | 2005-03-15 | Cyclops Genome Sciences, Ltd. | Modified polynucleotides and uses thereof |
WO2005058479A2 (en) | 2003-12-17 | 2005-06-30 | Praecis Pharmaceuticals, Inc. | Methods for synthesis of encoded libraries |
WO2006135786A2 (en) | 2005-06-09 | 2006-12-21 | Praecis Pharmaceuticals, Inc. | Methods for synthesis of encoded libraries |
WO2007062664A2 (en) | 2005-12-01 | 2007-06-07 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
US20070224607A1 (en) | 2005-10-28 | 2007-09-27 | Praecis Pharmaceuticals Incorporated | Methods for identifying compounds of interest using encoded libraries |
WO2010094036A1 (en) | 2009-02-13 | 2010-08-19 | X-Chem, Inc. | Methods of creating and screening dna-encoded libraries |
US20110104785A1 (en) * | 2009-11-05 | 2011-05-05 | Ramesh Vaidyanathan | Methods and kits for 3'-end-tagging of rna |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260032B1 (en) * | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5025388A (en) | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US6005087A (en) * | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5723289A (en) | 1990-06-11 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | Parallel selex |
JP2780572B2 (en) | 1991-09-13 | 1998-07-30 | 株式会社島津製作所 | Enzymatic synthesis of oligonucleotides and use of oligonucleotides as primers |
US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
WO1993006121A1 (en) | 1991-09-18 | 1993-04-01 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
HUT72495A (en) | 1992-10-01 | 1996-05-28 | Cold Spring Harbor Lab | Complex combinatorial chemical libraries encoded with tags |
US6503759B1 (en) | 1992-10-01 | 2003-01-07 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
US5681943A (en) | 1993-04-12 | 1997-10-28 | Northwestern University | Method for covalently linking adjacent oligonucleotides |
ATE246702T1 (en) | 1993-04-12 | 2003-08-15 | Univ Northwestern | METHOD FOR PREPARING OLIGONUCLEOTIDES |
US5840485A (en) | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
AU686186B2 (en) | 1993-05-27 | 1998-02-05 | Aventisub Ii Inc. | Topologically segregated, encoded solid phase libraries |
AU7323194A (en) | 1993-07-02 | 1995-01-24 | Lynx Therapeutics, Inc. | Synthesis of branched nucleic acids |
US5571903A (en) | 1993-07-09 | 1996-11-05 | Lynx Therapeutics, Inc. | Auto-ligating oligonucleotide compounds |
US6087186A (en) | 1993-07-16 | 2000-07-11 | Irori | Methods and apparatus for synthesizing labeled combinatorial chemistry libraries |
GB9315847D0 (en) | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
AU7390994A (en) | 1993-08-25 | 1995-03-21 | Symbicom Aktiebolag | Molecular modelling and drug design |
US5658782A (en) | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
GB2298863B (en) | 1993-11-02 | 1998-03-11 | Affymax Tech Nv | Apparatus and process for the synthesis of diverse compounds especially for generating and screening compound libraries |
US6117976A (en) | 1993-11-04 | 2000-09-12 | Medical Research Council | Manufacture and use of polypeptides tagged using binding molecules |
EP0736103A4 (en) | 1993-12-17 | 1999-07-28 | Roger S Cubicciotti | Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices |
US6936477B2 (en) | 1994-04-13 | 2005-08-30 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
JPH08268A (en) | 1994-06-16 | 1996-01-09 | Koichi Nishigaki | Method of producing ligated double-stranded dna |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5525734A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies N.V. | Methods for synthesizing diverse collections of pyrrolidine compounds |
MX9700725A (en) | 1994-07-26 | 1997-05-31 | Scripps Research Inst | Soluble combinatorial libraries. |
US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US5695934A (en) | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
USRE43097E1 (en) | 1994-10-13 | 2012-01-10 | Illumina, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
US6654505B2 (en) | 1994-10-13 | 2003-11-25 | Lynx Therapeutics, Inc. | System and apparatus for sequential processing of analytes |
US6013445A (en) | 1996-06-06 | 2000-01-11 | Lynx Therapeutics, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
WO1996038726A1 (en) | 1995-05-30 | 1996-12-05 | Ecole Polytechnique Federale De Lausanne (Epfl) | Covalently immobilized phospholipid bilayers on solid surfaces |
US5780613A (en) | 1995-08-01 | 1998-07-14 | Northwestern University | Covalent lock for self-assembled oligonucleotide constructs |
DE19646372C1 (en) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Conjugates of polypeptide and encoding nucleic acid |
US5780231A (en) | 1995-11-17 | 1998-07-14 | Lynx Therapeutics, Inc. | DNA extension and analysis with rolling primers |
US5763175A (en) | 1995-11-17 | 1998-06-09 | Lynx Therapeutics, Inc. | Simultaneous sequencing of tagged polynucleotides |
US5962228A (en) | 1995-11-17 | 1999-10-05 | Lynx Therapeutics, Inc. | DNA extension and analysis with rolling primers |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US5846839A (en) | 1995-12-22 | 1998-12-08 | Glaxo Group Limited | Methods for hard-tagging an encoded synthetic library |
US6027890A (en) | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
DE19642751A1 (en) | 1996-10-16 | 1998-04-23 | Deutsches Krebsforsch | Saccharide library |
JP3692542B2 (en) | 1997-01-21 | 2005-09-07 | ザ ジェネラル ホスピタル コーポレーション | Protein selection using RNA-protein fusions |
US5888737A (en) | 1997-04-15 | 1999-03-30 | Lynx Therapeutics, Inc. | Adaptor-based sequence analysis |
CA2291180A1 (en) | 1997-05-23 | 1998-11-26 | Lynx Therapeutics, Inc. | System and apparatus for sequential processing of analytes |
US6969488B2 (en) | 1998-05-22 | 2005-11-29 | Solexa, Inc. | System and apparatus for sequential processing of analytes |
US20020034732A1 (en) | 1997-07-30 | 2002-03-21 | Daniel J. Capon | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
WO1999010485A1 (en) | 1997-08-29 | 1999-03-04 | Selective Genetics, Inc. | Methods using phage display for selecting internalizing ligands for gene delivery |
US6607878B2 (en) | 1997-10-06 | 2003-08-19 | Stratagene | Collections of uniquely tagged molecules |
DE19928591A1 (en) * | 1998-06-22 | 1999-12-23 | Roxana Havlina | Production of polymers from nucleotide and/or non-nucleotide units using RNA ligase, useful for |
US6846655B1 (en) | 1998-06-29 | 2005-01-25 | Phylos, Inc. | Methods for generating highly diverse libraries |
AU6502599A (en) | 1998-10-05 | 2000-04-26 | Lynx Therapeutics, Inc. | Enzymatic synthesis of oligonucleotide tags |
US7479472B1 (en) | 1998-10-19 | 2009-01-20 | The Board Of Trustees Of The Leland Stanford Junior University | DNA-templated combinatorial library chemistry |
US5942609A (en) | 1998-11-12 | 1999-08-24 | The Porkin-Elmer Corporation | Ligation assembly and detection of polynucleotides on solid-support |
DE69935248T2 (en) | 1998-12-02 | 2007-11-08 | Adnexus Therapeutics, Inc., Waltham | DNA PROTEIN FUSIONS AND APPLICATIONS THEREOF |
US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
US7033753B1 (en) | 1999-01-15 | 2006-04-25 | University Of Rochester | Compositions and methods for nonenzymatic ligation of oligonucleotides and detection of genetic polymorphisms |
EP1208219A1 (en) | 1999-04-08 | 2002-05-29 | Pavel Sergeev | Synthesis of biologically active compounds in cells |
US7270969B2 (en) | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
WO2001016352A1 (en) | 1999-08-27 | 2001-03-08 | Phylos, Inc. | Methods for encoding and sorting in vitro translated proteins |
AU7703400A (en) | 1999-09-14 | 2001-04-17 | Xenoport, Inc. | Substrates and screening methods for transport proteins |
JP2003511362A (en) | 1999-10-04 | 2003-03-25 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー | New carbamates and ureas |
US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
WO2001062772A2 (en) | 2000-02-23 | 2001-08-30 | Xenoport, Inc. | Self-encoded combinatorial synthesis of compound multiplets |
US6936467B2 (en) * | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
US7998673B2 (en) | 2000-03-29 | 2011-08-16 | Lgc Limited | Hybridisation beacon and method of rapid sequence detection and discrimination |
US6479262B1 (en) * | 2000-05-16 | 2002-11-12 | Hercules, Incorporated | Solid phase enzymatic assembly of polynucleotides |
US6994963B1 (en) | 2000-07-10 | 2006-02-07 | Ambion, Inc. | Methods for recombinatorial nucleic acid synthesis |
US20020072887A1 (en) | 2000-08-18 | 2002-06-13 | Sandor Szalma | Interaction fingerprint annotations from protein structure models |
US6627748B1 (en) | 2000-09-11 | 2003-09-30 | The Trustees Of Columbia University In The City Of New York | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
EP1331572B1 (en) | 2000-09-20 | 2012-08-08 | ARKRAY, Inc. | Client support system |
CA2427109A1 (en) | 2000-10-27 | 2002-05-02 | Research Development Foundation | In vitro selection of signaling aptamers |
JP2002315577A (en) | 2000-11-14 | 2002-10-29 | Gencom Co | Method for constructing nucleic acid library |
US20030049616A1 (en) | 2001-01-08 | 2003-03-13 | Sydney Brenner | Enzymatic synthesis of oligonucleotide tags |
PT1423400E (en) | 2001-03-19 | 2006-12-29 | Harvard College | Evolving new molecular function |
US20030143561A1 (en) | 2001-06-20 | 2003-07-31 | Nuevolution A/S | Nucleoside derivatives for library preparation |
US7727713B2 (en) | 2001-06-20 | 2010-06-01 | Nuevolution A/S | Templated molecules and methods for using such molecules |
US20060234231A1 (en) | 2001-06-20 | 2006-10-19 | Nuevolution A/S | Microarrays displaying encoded molecules |
RU2004101289A (en) | 2001-06-20 | 2005-07-10 | Нуэволюшн А/С (Dk) | METHOD FOR SYNTHESIS OF THE MOLECULE ON THE MATRIX |
DK1483585T3 (en) | 2002-03-08 | 2009-06-22 | Eidgenoess Tech Hochschule | Encoded, self-assembling chemical libraries (ESACHEL) |
WO2003078446A2 (en) | 2002-03-15 | 2003-09-25 | Nuevolution A/S | A building block forming a c-c or a c-hetero atom bond upon reaction |
US20060166197A1 (en) | 2002-03-15 | 2006-07-27 | Gouliaev Alex H | Building block capable of transferring a functional entity |
AU2003253069A1 (en) | 2002-03-15 | 2003-09-29 | Nuevolution A/S | A building block forming a c-c bond upon reaction |
EP1487848A2 (en) | 2002-03-15 | 2004-12-22 | Nuevolution A/S | A building block forming a c=c double bond upon reaction |
DE60324778D1 (en) | 2002-03-15 | 2009-01-02 | Nuevolution As | AN IMPROVED METHOD FOR SYNTHESIS OF MATTRESS-RELATED MOLECULES |
AU2003240436A1 (en) | 2002-06-20 | 2004-01-06 | Nuevolution A/S | Microarrays displaying encoded molecules |
WO2004010101A2 (en) | 2002-07-18 | 2004-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of chemical ligation using fluorescence quenching leaving groups |
AU2003242516A1 (en) | 2002-07-23 | 2004-02-09 | Nuevolution A/S | Gene shuffling by template switching |
EP1539980B1 (en) | 2002-08-01 | 2016-02-17 | Nuevolution A/S | Library of complexes comprising small non-peptide molecules and double-stranded oligonucleotides identifying the molecules |
WO2004016767A2 (en) | 2002-08-19 | 2004-02-26 | The President And Fellows Of Harvard College | Evolving new molecular function |
WO2004024929A2 (en) | 2002-09-12 | 2004-03-25 | Nuevolution A/S | Proximity-aided synthesis of templated molecules |
CN106337046B (en) | 2002-10-30 | 2021-03-23 | 纽韦卢森公司 | Method for synthesizing bifunctional complexes |
EP2175019A3 (en) | 2002-12-19 | 2011-04-06 | Nuevolution A/S | Quasirandom structure and function guided synthesis methods |
EP1597394A2 (en) | 2003-02-21 | 2005-11-23 | Nuevolution A/S | A method for obtaining structural information about an encoded molecule |
EP1597395A2 (en) | 2003-02-21 | 2005-11-23 | Nuevolution A/S | Method for producing second-generation library |
DE602004019764D1 (en) | 2003-03-20 | 2009-04-16 | Nuevolution As | LIGATION-RELATED CODING OF SMALL MOLECULES |
EP1652123A2 (en) | 2003-07-03 | 2006-05-03 | Biogen Idec MA Inc. | STRUCTURAL INTERACTION FINGERPRINT (SIFt) |
CN1836050A (en) | 2003-07-07 | 2006-09-20 | 单细胞系统公司 | Hairpin-labeled probes and methods of use |
EP1533385A1 (en) | 2003-09-05 | 2005-05-25 | Nuevolution A/S | Templated compounds for generation of encoded molecules and directional methods using such compounds |
WO2005026686A2 (en) | 2003-09-09 | 2005-03-24 | Compass Genetics, Llc | Multiplexed analytical platform |
ATE447626T1 (en) | 2003-09-18 | 2009-11-15 | Nuevolution As | METHOD FOR OBTAINING STRUCTURAL INFORMATION FROM ENCODED MOLECULES AND FOR SELECTING COMPOUNDS |
WO2005050224A2 (en) | 2003-11-13 | 2005-06-02 | Epitome Biosystems Inc. | Small molecule and peptide arrays and uses thereof |
US7972994B2 (en) | 2003-12-17 | 2011-07-05 | Glaxosmithkline Llc | Methods for synthesis of encoded libraries |
US20050153321A1 (en) | 2003-12-30 | 2005-07-14 | Saba James A. | Libraries of multiple-ligand-conjugated nucleic acids |
AU2005214329A1 (en) | 2004-02-12 | 2005-09-01 | Population Genetics Technologies Ltd | Genetic analysis by sequence-specific sorting |
EP1723255B1 (en) | 2004-02-17 | 2010-12-29 | Nuevolution A/S | Method for enrichment involving elimination by mismatch hybridisation |
US7704925B2 (en) | 2004-03-22 | 2010-04-27 | Nuevolution A/S | Ligational encoding using building block oligonucleotides |
US7405287B2 (en) | 2004-08-03 | 2008-07-29 | Board Of Regents, The University Of Texas System | Method of treating a cancer |
US7745614B2 (en) | 2004-09-03 | 2010-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Universal linker compositions for the release or transfer of chemical agents from a polynucleotide |
WO2006047791A2 (en) | 2004-10-27 | 2006-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Dna-templated combinatorial library device and method for use |
DE602005012139D1 (en) | 2004-11-08 | 2009-02-12 | Vipergen Aps | STRUCTURAL NUCLEIC ACID-LED CHEMICAL SYNTHESIS |
ATE420170T1 (en) | 2004-11-22 | 2009-01-15 | Peter Birk Rasmussen | MATTRICE-DIRECTED SPLIT-AND-MIX SYNTHESIS OF SMALL MOLECULE LIBRARIES |
CA2591582A1 (en) | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
CN101090979A (en) * | 2004-12-22 | 2007-12-19 | 埃克斯魁恩公司 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same |
WO2006079061A2 (en) * | 2005-01-21 | 2006-07-27 | President And Fellows Of Harvard College | Free reactant use in nucleic acid-templated synthesis |
US7407757B2 (en) | 2005-02-10 | 2008-08-05 | Population Genetics Technologies | Genetic analysis by sequence-specific sorting |
US7393665B2 (en) | 2005-02-10 | 2008-07-01 | Population Genetics Technologies Ltd | Methods and compositions for tagging and identifying polynucleotides |
WO2006099604A2 (en) | 2005-03-16 | 2006-09-21 | Compass Genetics, Llc | Methods and compositions for assay readouts on multiple analytical platforms |
US20090035824A1 (en) | 2005-06-17 | 2009-02-05 | Liu David R | Nucleic acid-templated chemistry in organic solvents |
CA2616404A1 (en) | 2005-07-26 | 2007-02-01 | Oregon Health & Science University | Nanoparticle probes for capture, sorting and placement of targets |
US20090005256A1 (en) | 2005-07-29 | 2009-01-01 | Bittker Joshua A | Analysis of Encoded Chemical Libraries |
CA2624634A1 (en) | 2005-10-03 | 2007-04-12 | Applera Corporation | Compositions, methods, and kits for amplifying nucleic acids |
WO2007087312A2 (en) | 2006-01-23 | 2007-08-02 | Population Genetics Technologies Ltd. | Molecular counting |
WO2007124758A1 (en) | 2006-05-03 | 2007-11-08 | Vipergen Aps | A method for preparing compounds by nucleic acid directed synthesis |
WO2008050661A1 (en) | 2006-10-26 | 2008-05-02 | Sumitomo Chemical Company, Limited | Method for producing asymmetric copper complex crystal |
CN101219219B (en) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | Complex containing vascellum chalone or fragment, preparation method and application thereof |
ATE516371T1 (en) | 2007-10-22 | 2011-07-15 | Lgc Ltd | OLIGONUCLEOTIDES AND USES THEREOF |
JP4940311B2 (en) | 2007-11-19 | 2012-05-30 | 国立大学法人北陸先端科学技術大学院大学 | Photoresponsive artificial nucleotide with optical cross-linking ability |
WO2009077173A2 (en) | 2007-12-19 | 2009-06-25 | Philochem Ag | Dna-encoded chemical libraries |
US20120107840A1 (en) | 2008-04-09 | 2012-05-03 | Sru Biosystems, Inc | Methods for Label Free Testing of Cells |
JP4814904B2 (en) | 2008-04-16 | 2011-11-16 | 国立大学法人北陸先端科学技術大学院大学 | Method for sequence-selective purification of nucleic acids |
JP5774474B2 (en) * | 2008-05-02 | 2015-09-09 | エピセンター テクノロジーズ コーポレーションEpicentre Technologies Corporation | Tagging by selective 5 'ligation to RNA |
TW201011006A (en) | 2008-06-16 | 2010-03-16 | Nuevolution As | IAP binding compounds |
KR20110036638A (en) | 2008-07-25 | 2011-04-07 | 리차드 더블유. 와그너 | Protein screening methods |
EP2391639A1 (en) | 2009-01-30 | 2011-12-07 | Oxford Nanopore Technologies Limited | Enzyme mutant |
AU2010213497A1 (en) | 2009-02-13 | 2011-08-25 | X-Body, Inc. | Identification of nucleic acid delivery vehicles using DNA display |
EP2396430B1 (en) | 2009-02-16 | 2013-05-01 | Epicentre Technologies Corporation | Template-independent ligation of single-stranded dna |
CA2767408C (en) | 2009-07-06 | 2018-01-23 | Trilink Biotechnologies | Chemically modified ligase cofactors, donors and acceptors |
DE102009058769A1 (en) * | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperature-dependent activation of catalytic nucleic acids for controlled drug release |
US20110237535A1 (en) | 2010-03-26 | 2011-09-29 | Sru Biosystems, Inc. | Use of Induced Pluripotent Cells and other Cells for Screening Compound Libraries |
EP3540059A1 (en) | 2010-04-16 | 2019-09-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
EP2686349B1 (en) | 2011-03-15 | 2020-12-09 | X-Body, Inc. | Antibody screening methods |
US8846883B2 (en) | 2011-08-16 | 2014-09-30 | University Of Southhampton | Oligonucleotide ligation |
EA032438B1 (en) | 2011-09-07 | 2019-05-31 | Икс-Чем, Инк. | Methods for tagging dna-encoded libraries |
NZ739931A (en) | 2012-07-13 | 2019-08-30 | X Chem Inc | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
GB201322692D0 (en) | 2013-12-20 | 2014-02-05 | Philochem Ag | Production of encoded chemical libraries |
-
2012
- 2012-09-07 EA EA201490534A patent/EA032438B1/en not_active IP Right Cessation
- 2012-09-07 JP JP2014529907A patent/JP6674738B2/en not_active Expired - Fee Related
- 2012-09-07 KR KR1020207017041A patent/KR102242879B1/en active IP Right Grant
- 2012-09-07 DK DK12830083.7T patent/DK2748357T3/en active
- 2012-09-07 WO PCT/US2012/054228 patent/WO2013036810A1/en active Application Filing
- 2012-09-07 MX MX2014002854A patent/MX360438B/en active IP Right Grant
- 2012-09-07 CA CA3077662A patent/CA3077662A1/en not_active Abandoned
- 2012-09-07 US US14/343,306 patent/US10865409B2/en active Active
- 2012-09-07 ES ES18158771T patent/ES2852073T3/en active Active
- 2012-09-07 ES ES12830083.7T patent/ES2675111T3/en active Active
- 2012-09-07 SG SG11201400374TA patent/SG11201400374TA/en unknown
- 2012-09-07 SG SG10201605812YA patent/SG10201605812YA/en unknown
- 2012-09-07 BR BR112014005205A patent/BR112014005205A2/en active Search and Examination
- 2012-09-07 EP EP18158771.8A patent/EP3351631B1/en not_active Revoked
- 2012-09-07 EP EP20205449.0A patent/EP3828271A1/en not_active Withdrawn
- 2012-09-07 KR KR1020147007749A patent/KR102124613B1/en active IP Right Grant
- 2012-09-07 CA CA2848023A patent/CA2848023C/en not_active Expired - Fee Related
- 2012-09-07 CN CN201280053930.2A patent/CN103998658B/en not_active Expired - Fee Related
- 2012-09-07 AP AP2014007483A patent/AP2014007483A0/en unknown
- 2012-09-07 AU AU2012304387A patent/AU2012304387B2/en not_active Ceased
- 2012-09-07 IN IN2574CHN2014 patent/IN2014CN02574A/en unknown
- 2012-09-07 DK DK18158771.8T patent/DK3351631T3/en active
- 2012-09-07 EP EP12830083.7A patent/EP2748357B1/en not_active Revoked
-
2014
- 2014-02-27 IL IL231191A patent/IL231191B/en unknown
- 2014-03-07 MX MX2018013367A patent/MX2018013367A/en unknown
-
2017
- 2017-02-20 AU AU2017201146A patent/AU2017201146B2/en not_active Ceased
-
2018
- 2018-05-08 JP JP2018089600A patent/JP6703034B2/en not_active Expired - Fee Related
-
2019
- 2019-01-23 HK HK19101192.3A patent/HK1258815A1/en unknown
- 2019-02-12 AU AU2019200965A patent/AU2019200965B2/en not_active Ceased
-
2020
- 2020-05-07 US US16/869,271 patent/US20210002630A1/en not_active Abandoned
- 2020-05-07 JP JP2020081691A patent/JP2020176121A/en active Pending
- 2020-12-27 IL IL279796A patent/IL279796A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867290B2 (en) * | 1999-04-30 | 2005-03-15 | Cyclops Genome Sciences, Ltd. | Modified polynucleotides and uses thereof |
WO2005058479A2 (en) | 2003-12-17 | 2005-06-30 | Praecis Pharmaceuticals, Inc. | Methods for synthesis of encoded libraries |
WO2006135786A2 (en) | 2005-06-09 | 2006-12-21 | Praecis Pharmaceuticals, Inc. | Methods for synthesis of encoded libraries |
US20070224607A1 (en) | 2005-10-28 | 2007-09-27 | Praecis Pharmaceuticals Incorporated | Methods for identifying compounds of interest using encoded libraries |
WO2007062664A2 (en) | 2005-12-01 | 2007-06-07 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
WO2010094036A1 (en) | 2009-02-13 | 2010-08-19 | X-Chem, Inc. | Methods of creating and screening dna-encoded libraries |
US20110104785A1 (en) * | 2009-11-05 | 2011-05-05 | Ramesh Vaidyanathan | Methods and kits for 3'-end-tagging of rna |
Non-Patent Citations (3)
Title |
---|
GREENE: "Protective Groups in Organic Synthesis", 2007, JOHN WILEY & SONS |
JAROSCH ET AL., NUCLEIC ACIDS RES., vol. 34, 2006, pages E86 |
See also references of EP2748357A1 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2186897B1 (en) * | 2002-03-15 | 2016-02-17 | Nuevolution A/S | An improved method for synthesising templated molecules |
US12018336B2 (en) | 2008-09-05 | 2024-06-25 | Aqtual, Inc. | Methods for sequencing samples |
US11965211B2 (en) | 2008-09-05 | 2024-04-23 | Aqtual, Inc. | Methods for sequencing samples |
US9359601B2 (en) | 2009-02-13 | 2016-06-07 | X-Chem, Inc. | Methods of creating and screening DNA-encoded libraries |
US11168321B2 (en) | 2009-02-13 | 2021-11-09 | X-Chem, Inc. | Methods of creating and screening DNA-encoded libraries |
US10072283B2 (en) | 2010-09-24 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
EP2748357B1 (en) | 2011-09-07 | 2018-04-04 | X-Chem, Inc. | Methods for tagging dna-encoded libraries |
US10865409B2 (en) | 2011-09-07 | 2020-12-15 | X-Chem, Inc. | Methods for tagging DNA-encoded libraries |
EP3351631B1 (en) | 2011-09-07 | 2020-11-04 | X-Chem, Inc. | Methods for tagging dna-encoded libraries |
JP2018138590A (en) * | 2011-09-07 | 2018-09-06 | エックス−ケム インコーポレイテッド | Methods for tagging dna-encoded libraries |
EP3851529A1 (en) * | 2012-07-13 | 2021-07-21 | X-Chem, Inc. | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
EP3392338A1 (en) * | 2012-07-13 | 2018-10-24 | X-Chem, Inc. | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
EP2872680A4 (en) * | 2012-07-13 | 2016-01-27 | Chem Inc X | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
US11674135B2 (en) | 2012-07-13 | 2023-06-13 | X-Chem, Inc. | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
AU2018202665B2 (en) * | 2012-07-13 | 2020-06-25 | X-Chem, Inc. | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
EP3392338B1 (en) | 2012-07-13 | 2020-12-09 | X-Chem, Inc. | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
AU2013289993B2 (en) * | 2012-07-13 | 2018-05-10 | X-Chem, Inc. | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
EP2872680B1 (en) | 2012-07-13 | 2018-04-04 | X-Chem, Inc. | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
US10240147B2 (en) | 2013-12-20 | 2019-03-26 | Philochem Ag | Production of encoded chemical libraries |
EP3083957B1 (en) | 2013-12-20 | 2018-05-23 | Philochem AG | Production of encoded chemical libraries |
WO2015091207A1 (en) * | 2013-12-20 | 2015-06-25 | Philochem Ag | Production of encoded chemical libraries |
WO2015135856A1 (en) * | 2014-03-14 | 2015-09-17 | Philochem Ag | Purification of dna-conjugate products |
AU2015374309B2 (en) * | 2014-12-30 | 2020-06-11 | X-Chem, Inc. | Methods for tagging DNA-encoded libraries |
US11407993B2 (en) * | 2017-02-14 | 2022-08-09 | Technische Universitaet Dortmund | Method for the synthesis of DNA conjugates by micellar catalysis |
EP3515880B1 (en) | 2017-03-17 | 2023-05-10 | Hitgen Inc. | Methods and compositions for synthesis of encoded libraries |
US11667941B2 (en) | 2018-01-12 | 2023-06-06 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
WO2019140353A1 (en) * | 2018-01-12 | 2019-07-18 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
WO2019157693A1 (en) * | 2018-02-14 | 2019-08-22 | 深圳劲宇生物科技有限公司 | Dna-coded molecular library and widely-applicable compound screening method |
WO2019157692A1 (en) * | 2018-02-14 | 2019-08-22 | 深圳劲宇生物科技有限公司 | Dna-encoded molecular library and target restriction-free compound screening method |
EP3924509A4 (en) * | 2019-05-09 | 2022-12-28 | Pacific Biosciences Of California, Inc. | Compositions and methods for improved cdna synthesis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019200965B2 (en) | Methods for tagging DNA-encoded libraries | |
AU2020239663A1 (en) | DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases | |
WO2016109423A1 (en) | Methods for tagging dna-encoded libraries | |
NZ621592B2 (en) | Methods for tagging dna-encoded libraries | |
NZ722289B2 (en) | Methods for tagging dna-encoded libraries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12830083 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014529907 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 231191 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2848023 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/002854 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2012304387 Country of ref document: AU Date of ref document: 20120907 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147007749 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012830083 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490534 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005205 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14343306 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112014005205 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140306 |